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1 Introduction 
1.1 Cancer 
Cancer is a major health problem worldwide. It is the second leading cause of 
death globally and 8.8 million people died from cancer in 2015 
(http://www.who.int/features/factfiles/cancer/en/). Ten leading cancer types for the 
estimated deaths in the United States are shown in Figure 1 (Siegel et al., 2018), 
notably in both genders lung cancer is most common cancer type, which leads to 
death. 
 
 
 
 
Figure 1. Estimated deaths caused by ten leading cancer types in the United States. 
Estimates are rounded to the nearest 10 and cases exclude basal cell and squamous cell 
skin cancers and in situ carcinoma except urinary bladder. Figure and legend are taken from 
(Siegel et al., 2018). 
 
 Cancer is a complex disease that involves dynamic changes in the genome.  
There are more than 200 different tumor entities that reflect differences in cell of 
origin, acquired somatic mutations, wide range of altered transcriptional networks 
and influences of local tissue microenvironments (Lambert et al., 2017). Hanahan 
and Weinberg grouped different biological capabilities that are acquired during 
multistep development of human tumors into ten “hallmarks of cancer” as shown in 
Figure 2 (Hanahan and Weinberg, 2011). These hallmarks include sustaining 
proliferative signaling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, activating invasion and metastasis, 
reprogramming of energy metabolism, avoiding immune destruction, genomic 
instability and tumor microenvironment. 
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Figure 2.  The hallmarks of cancer.   
Ten fundamental features acquired during tumor development. The figure is taken from 
(Hanahan and Weinberg, 2011). 
 
1.2 Colorectal cancer 
Colorectal cancer (CRC) is one of the major health concerns and the 4TH 
leading cause of cancer-related deaths worldwide (McGuire, 2016). Also in United 
States it is the 3rd leading cause of cancer-related deaths (Siegel et al., 2018). It is 
estimated that 140,250 patients will be diagnosed with CRC and that 50,630 patients 
will die from the disease by 2018 in the US (Siegel et al., 2018).  
CRC is a multistep process (Figure 3) and histologically it begins with early 
changes from normal to hyperproliferative epithelium followed by the development of 
adenomas, which are thought to be precursors of carcinomas (Cherry, 2011). These 
histological changes are driven by the genetic or epigenetic inactivation of tumor 
suppressor genes and activation of oncogenes (Fearon and Vogelstein, 1990). In 
most cases, colorectal tumorigenesis begins with stabilization of the key transcription 
factor β-catenin by loss of APC or more rarely, by activating mutations in the CTNNB 
gene (Morin et al., 1997). This results in constitutive activation of the Wnt-pathway 
(Ashton-Rickardt et al., 1989), the major signaling pathway in self-renewal of the 
intestinal stem-cell compartment. Additional mutations, such as KRAS, lead to early 
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adenomas, whereas TP53 inactivation in late stages has been associated with 
invasive carcinomas and metastasis formation (Fearon and Vogelstein, 1990; Jones 
et al., 2008). 
 
 
 
Figure 3. Canonical mechanisms of sporadic colorectal cancer (CRC) and colitis-
associated cancer (CAC) development.  
Upper panel represents molecular and morphological changes during sporadic CRC 
progression; lower panel represents molecular and morphological changes during CAC 
progression. Sequence and frequency of these changes show differences between CRC and 
CAC. The figure is taken from (West et al., 2015). 
 
1.3 Colitis-associated cancer  
Inflammatory bowel disease (IBD) is a chronic relapsing condition characterized 
by intestinal damage which is caused by a barrier defect and microbiota influx 
resulting in high levels of inflammation (Francescone et al., 2015). The two major 
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forms of IBD are ulcerative colitis (UC) and Crohn´s Disease (CD), which both may 
progress to colitis-associated colon-cancer (CAC) (Grivennikov, 2013). CD increases 
the cumulative risk of CAC by up to 8% and UC up to 20 % after 30 years of active 
disease (Canavan et al., 2006; Eaden et al., 2001; Rubin et al., 2012).   
CAC and CRC display similarities, such as microsatellite instability (MSI), 
activation of the oncogene KRAS, activation of COX2, mutation and eventual loss of 
heterozygosity (LOH) of TP53 and mutation of APC. However, the sequence and 
frequency of these events differ between CAC and CRC. For example, mutations in 
APC occur early in CRC, whereas they occur in later stages of CAC. In addition,  
TP53 mutations occur early in CAC and in a late stage of CRC ((West et al., 2015) 
Figure 3). 
To understand the molecular changes leading to the colorectal cancer 
development, different mouse models have been developed that mimic colitis-
associated colon cancer and sporadic colon cancer. There are animal models, which 
spontaneously develop CAC, such as IL10 and Gαi2 knockout mice and chemically 
induced CAC models, like those receiving dextran sulphate sodium (DSS) or a 
combination of DSS with azoxymethane (AOM), 1,2-dimethylhydrazine (DHM) or iron 
(Kanneganti et al., 2011). 
DSS treatment induces apoptosis within the intestinal epithelium, and therefore 
disrupting the epithelial barrier, allowing penetration of commensal microbiota into 
the lamina propria. This triggers an inflammatory response resulting in an 
upregulation of proinflammatory cytokines such as IL2, IL4 and IL6 (Clapper et al., 
2007). Repetitive administration of DSS induces chronic colitis. In combination with a 
preceding treatment of pro-carcinogen AOM it triggers adenoma development in the 
distal colon resembling the CAC frequently observed in UC patients (Clapper et al., 
2007). These adenomas show signs of Wnt pathway activation as it is observed in 
human CACs frequently (Aust et al., 2001). 
Mouse models of CAC are excellent tools to decipher the underlying 
mechanisms which connect inflammation and cancer (Grivennikov, 2013). In mouse 
models, like those used in this study, single injection of the carcinogen AOM is not 
sufficient to induce colonic tumor formation unless coupled with the induction of 
chronic colitis. However, multiple injections of the carcinogen (AOM) induce colonic 
tumorigenesis within a time period of 4 months. In the present study, this treatment 
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scheme is used as a model of sporadic carcinogenesis in combination with Tp53 
deficiency. 
 
1.4 The P53 tumor suppressor protein 
The P53 protein, which is encoded by TP53 gene, was also named as the 
“guardian of genome” since it is a key player in the DNA damage response (Lane, 
1992). Since its discovery in 1979, P53 has been studied extensively. After its 
discovery, it was thought to be an oncogene. However, studies in 1989 demonstrated 
that wild-type P53 suppresses growth and oncogenic transformation (Finlay et al., 
1989). Moreover,  inactivating TP53 mutations are common in human tumors (Baker 
et al., 1989). These and many subsequent studies confirmed its role as a major 
tumor suppressor.  
 P53 protein is a transcription factor, which is activated in response to cellular 
stresses, such as oncogenic signals, DNA damage and hypoxia (Bieging et al., 
2014). It promotes the expression of a large number of target genes that mediate 
senescence, cell cycle arrest and apoptosis. The wide range of regulators that 
control P53 activity in many distinct biological processes were summarized in a 
recent review ((Kastenhuber and Lowe, 2017) Figure 4.). The responses to P53 
activation highly depend on cell type, epigenetic state, tissue microenvironment and 
the kind of  cellular stress (Kastenhuber and Lowe, 2017). In unstressed cells, P53 is 
subjected to proteosomal degradation by binding to its negative regulator Mdm2. 
Various cellular stresses lead to disruption of the P53-Mdm2 interaction by inducing 
posttranslational modifications of both P53 and Mdm2. This results in P53 
stabilization and activation (Kenzelmann Broz and Attardi, 2010). 
In addition, numerous studies showed the role of P53 in autophagy (Crighton et 
al., 2006), mitochondrial respiration (Bensaad et al., 2006; Matoba et al., 2006) and 
protection of the genome from oxidative stress (Sablina et al., 2005). P53 was 
reported to support anti-oxidant activity, increase glutamine catabolism, 
downregulate lipid synthesis, stimulate gluconeogenesis and increase fatty acid 
oxidation (Kruiswijk et al., 2015). Furthermore, loss of Tp53 in IECs induces 
epithelial-mesenchymal transition (EMT), which promotes formation of an 
inflammatory microenvironment by increasing intestinal permeability in a carcinogen-
induced CRC model (Schwitalla et al., 2013). 
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TP53 is inactivated by mutations in cancer and the frequencies of TP53 
mutations varies between different cancer entities ranging from ~10% in 
hematopoietic malignancies (Peller and Rotter, 2003) to ~50-70% in colorectal 
cancer (Iacopetta, 2003). The majority of TP53 mutations are missense mutations in 
the DNA binding domain (Kastenhuber and Lowe, 2017) that block the recognition of 
genomic aberrations. 
 
 
Figure 4. The P53 network. 
A wide variety of regulators govern the activity of P53 (top), which, in turn, controls many 
distinct biological processes (bottom). Each node represents a gene and each line 
represents an interaction. Direct P53 inputs are indicated as blue lines and direct P53 
outputs are indicated as red lines. Noticeably, P53 controls effector processes by activating 
multiple target genes. Downstream pathways are highly interconnected (gray lines). Figure 
and legend are taken from (Kastenhuber and Lowe, 2017). 
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TP53 inactivation occurs at the late stages of colorectal tumorigenesis and 
mutations in TP53 are associated with invasion, metastasis and poor patient survival 
(Jones et al., 2008; Levine and Oren, 2009). Furthermore, the majority (92.1%) of all 
TP53 missense mutations also occurs in the DNA binding domain in CRC (Bouaoun 
et al., 2016). During tumor progression, both somatic and germ-line mutations of 
TP53 are followed by loss of heterozygosity (LOH) within chromosome17p (Rivlin et 
al., 2011).   
 
1.5 microRNAs and the miR-34 family 
MicroRNAs (miRNAs) are a subset of small non-coding RNAs that are ~22 
nucleotides in length. miRNAs were initially discovered in Caenorhabditis elegans 
(Lee et al., 1993). The canonical miRNA biogenesis begins with the transcription of 
pri-miRNAs by RNA polymerase II from miRNA genes (Lee et al., 2004). In the next 
step, a microprocessor complex, that is composed of the ribonuclease enzyme 
Drosha and the RNA-binding protein DGCR8, cleaves the pri-miRNA to pre-miRNA 
(70 nucleotide-long precursor hairpin structures) (Gregory et al., 2004). The pre-
miRNA is then exported from the nucleus into cytoplasm by Exportin 5 
(XPO5)/RanGTP complex (Brownawell and Macara, 2002; O'Brien et al., 2018). In 
cytoplasm, the pre-miRNA is processed by RNase III protein Dicer, and transforms 
into 22 nucleotides long mature miRNA (Hutvagner et al., 2001; Ketting et al., 2001). 
Following this step, strands are incorporated into the RNA-induced silencing complex 
(RISC), which target specific mRNA molecules by RNA interference (Sontheimer, 
2005). The RISC complex consist of Dicer, the trans-activating response RNA-
binding protein (TRBP) and Argonaute 2 and it is sufficient for target recognition and 
cleavage of RNA molecules (Chendrimada et al., 2005; Pratt and MacRae, 2009). 
The target recognition is carried by the binding of an approximately seven 
nucleotides long stretch that is in the 5´end of the miRNA, with a complementary 
sequence that is found in the 3'-UTR of the target mRNA. This binding facilitates the 
recruitment of the RISC/Ago2 complex to the targeted mRNA, resulting in either 
inhibition of translation initiation and/or enhancement of mRNA degradation (Bartel, 
2009; Ha and Kim, 2014; Huntzinger and Izaurralde, 2011). 
Up to date more than 2000 miRNAs have been identified in humans and each 
individual miRNA can target hundreds of mRNAs (Hammond, 2015). Therefore, 
miRNAs regulate diverse cellular processes, such as cell cycle control, proliferation, 
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apoptosis, angiogenesis, migration, metabolism, autophagy, differentiation of stem 
cells, somatic cell reprogramming and cardiac aging (Rokavec et al., 2014a). 
Several miRNA encoding genes have been characterized as oncogenic (for 
example: miR-17-5p, miR-155, miR-221/222, miR-21,) or tumor suppressive (for 
example: let-7, miR-16-1, miR-15a, miR-34) (Peng and Croce, 2016). Tumor 
suppressive miRNAs are frequently down-regulated in many types of cancer and 
have been shown to play important roles during initiation and progression of cancer 
(Kohlhapp et al., 2015). miRNAs are frequently found in fragile and other cancer-
associated regions of chromosomes as shown by mapping of 186 human miRNA 
genes (Calin et al., 2004).  
In the recent years, the miR-34 family was shown to represent a central 
mediator of tumor suppression that inhibits several cancer related biological 
processes, such as proliferation, invasion and metastasis (Rokavec et al., 2014a). In 
Figure 5, regulation of the miR-34a family is summarized. Seed sequences of miR-
34a and miR-34c are identical, whereas seed sequence of the miR-34b is slightly 
different. Therefore miR-34a and miR-34c share common mRNA targets. miR-34a is 
ubiquitously expressed in mice and showed the highest expression in the brain 
(Bommer et al., 2007). miR-34b/c is predominantly expressed in the lung and almost 
not detected in other tissues (Bommer et al., 2007). In intestinal epithelia expression 
levels of miR-34a is approximately 1000-fold higher than miR-34b and miR-34c 
(Rokavec et al., 2014b). Several studies reported that miR-34a and miR-34b/c are 
direct p53 target genes (reviewed in (Hermeking, 2007)). Among the p53-induced 
microRNAs miR-34a stands out in numerous comprehensive expression studies as 
the miRNA with the most pronounced induction (Hermeking, 2012). miR-34a is 
thought to have a central role for p53-mediated tumor suppression conferred by 
miRNAs which is presumably comparable to the pivotal role of p21 among the protein 
coding genes induced by p53. Meanwhile, numerous studies have documented the 
common inactivation of miR-34a/b/c by genetic and epigenetic mechanisms in 
diverse types of tumors (see review by (Rokavec et al., 2014a)). MIR34A is silenced 
by CpG methylation in late stage colorectal tumors (Wang et al., 2016). 
miR-34 inactivation alone was not found to be tumorigenic by itself or in 
combination with an activated c-Myc gene in B-cells (Concepcion et al., 2012). 
However, when additional pro-tumorigenic challenges or other genetic changes were 
introduced, miR-34 loss promoted tumor formation and/or progression in mice. For 
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example, we have shown cooperation between Tp53 and miR-34a/b/c loss in a 
mouse model of prostate cancer (Cheng et al., 2014). 
 
 
 
Figure 5. Genomic structure and regulation of the miR-34 family members.  
Structure of the miR-34a and miR-34b/c genes. Green and red boxes represent exons and 
miRNA hairpins, respectively. Horizontal arrows mark transcription start sites. The 
transcription factors p53, ELK1, and FoxO3a induce, whereas STAT3 and EMT-TF repress 
the transcription of miR-34 genes. EMT-TFs represent EMT-inducing transcription factors, 
such as SNAIL and ZEB1/2. Figure and legend are taken from (Rokavec et al., 2014a). 
 
In addition, deletion of one allele of miR-34a in combination with Mdm4 
activation was shown to cause adenocarcinomas of the lung (Okada et al., 2014). 
Recently, our group reported that Mir34a and MiR34b/c cooperatively suppress 
adenoma formation in APCmin mice, which represent a model for hereditary colon 
cancer, i.e. familial adenomatous polyposis (FAP) (Jiang and Hermeking, 2017). 
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1.6 IL6/IL6R/STAT3 Pathway 
IL6 is a growth factor in cancer and an inflammatory, anti-apoptotic cytokine 
that is linked to NF-κB and STAT3 signaling (Chalaris et al., 2012). It has various 
physiological functions such as, regulation of immune cell proliferation and 
differentiation (Garbers et al., 2018). IL6 binds to IL6R and the complex of IL6/IL6R 
binds to the trans-membrane glycoprotein 130 (gp130) to initiate intracellular 
signaling as shown in Figure 6 (Schaper and Rose-John, 2015). Protective immunity 
in host defense and tissue regeneration requires IL6-classic signaling whereas IL6-
trans-signaling promotes chronic inflammation and inflammatory tissue damage 
(Scheller et al., 2011). IL6R is expressed on a few cell types such as leukocytes, 
hepatocytes, and epithelial cells, whereas gp130 is expressed on all cells (Scheller et 
al., 2011). 
Blockage of IL6 receptor (IL6R) signaling with IL6R neutralizing antibody or 
sgp130Fc, a fusion protein that blocks IL6 trans-signaling, reduced cancer formation 
in a mouse model of colitis-associated carcinogenesis (Becker et al., 2004a). This 
study demonstrated the importance of IL6 trans-signaling, which is mediated by the 
soluble IL6R (s-IL6R) and that also induces IL6 signaling in cells that do not express 
IL6R but gp130. The soluble IL6R can either be generated from the membrane 
bound IL6R by proteolytic cleavage or produced as a spliced IL6R isoform. Together 
with IL6, the s-IL6R binds to gp130 expressing cells to promote STAT3 signaling 
(Becker et al., 2004a). Global IL6 deficiency and overexpression of sgp130Fc in 
transgenic mice further underlined the major role of IL6 signaling and s-IL6R during 
inflammation in vivo (Chalaris et al., 2012; Kopf et al., 1994; Rabe et al., 2008). 
Lesina et al. described the involvement of IL6 trans-signaling/Stat3/Socs3 in 
pancreatic intraepithelial neoplasia (PanIN) progression and pancreatic ductal 
adenocarcinoma (PDAC) development (Lesina et al., 2011). Recently, IL6 trans-
presentation has been described as a third mode of IL6 signaling in which dendritic 
cells (DCs) trans-present IL6 via their own IL6R to T cells (Heink et al., 2017).Trans-
presentation of IL6 leads to activation of the Jak/STAT pathway in the T cells and 
subsequently to the development of pathogenic Th17 cells (Heink et al., 2017). This 
third mode of IL6 signaling may allow new types of treatments for Th17 cell-driven 
diseases. 
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Figure 6. Three different modes of IL6 signaling. 
IL6 can either bind to the membrane-bound IL6 receptor (IL6R) (classic signaling), to soluble 
forms of the IL6R (trans-signaling), or it is presented from dendritic cells via their membrane-
bound IL6R to T cells (trans-presentation). Classic signaling is blocked by antibodies against 
IL6 and IL6R. Trans-signaling is blocked by antibodies against IL6 and IL6R and by the 
soluble form of glycoprotein 130 (sgp130Fc, Olamkicept). Trans-presentation is blocked only 
by antibodies against IL6R. All three modes of signaling converge on the plasma membrane 
in homodimerization of the signal-transducing receptor subunit gp130, activating the 
intracellular signaling cascades Janus kinase (JAK)–signal transducer and activator of 
transcription (STAT), mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase 
(PI3K) and YES-associated protein 1 (YAP). Figure and legend are taken from (Garbers et 
al., 2018). 
 
Moreover, in APCmin mice as well as in colitis-associated cancer and colon 
cancer mouse models, IL6 was shown to stimulate the proliferation of premalignant 
enterocytes (Fenton et al., 2006). Another report showed that myeloid cells derived 
IL6 acts as a tumor promoter during intestinal carcinogenesis by protecting intestinal 
epithelial cells from apoptosis and promoting the proliferation of premalignant cells 
(Bollrath et al., 2009; Grivennikov et al., 2009). Moreover, Naugler et al. reported that 
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IL6-deficient mice develop less N-nitrosodiethylamine (DEN)-induced hepatocellular 
carcinoma. Furthermore, they observed a gender-biased production of IL6, which 
was higher in male mice. Accordingly, the female mice were partially protected from 
hepatocellular carcinoma due to the inhibitory effect of estrogen on IL6 production, 
whereas male mice were highly susceptible (Naugler et al., 2007). In addition, IL11, 
whose effects on cancer cells are also mediated thorough the gp130/STAT3 pathway 
has been shown to have a predominant effect on tumor formation compared with IL6 
in mouse models of sporadic and inflammation associated colon cancer as well as 
gastric cancer (Putoczki et al., 2013).   
Therapeutic strategies have been developed to target the components of the 
IL6/IL6R/STAT3 pathway which are summarized in a recent review (Garbers et al., 
2018). Olamkicept (scgp130Fc), which selectively inhibits IL6 trans-signaling by 
sequestering IL6-sIL6R, is currently being evaluated in phase II clinical trials in IBD 
and ulcerative colitis patients. Anti-IL6R antibodies block classic, trans-signaling and 
trans-presentation, whereas scgp130Fc only inhibits trans-signaling. Notably, trans-
IL6 signaling promotes chronic inflammation and inflammatory tissue damage 
(Scheller et al., 2011).  
The transcription factor STAT3 is required for tissue repair and immune 
homeostasis and represents one of the main mediators of inflammation-induced 
carcinogenesis. Originally the STAT3 signaling pathway was described in 
hepatocytes as a component of the acute phase response in inflammation and later it 
has been recognized as a major driving factor in tumorigenesis and its activation has 
been shown in a variety of tumors including CRC (Bollrath and Greten, 2009). 
STAT3 is activated by various cytokines including the IL6 family of cytokines, 
comprised of IL6, IL11, ciliary neurotrophic factor (CNTF), oncostatin M (OSM), 
leukemia inhibitory factor (LIF), cardiotrophin 1 (CT-1), cardiotrophin-like cytokine 
(CLC), and IL-27 (Rose-John, 2018), the IL10 family members (Hutchins et al., 2013) 
and various growth factors, including epidermal growth factor (EGF), hepatocyte 
growth factor (HGF), and platelet derived growth factor (PDGF). Furthermore, non-
receptor tyrosine kinases, such as Abl or Src also activate STAT3 (Chakraborty et 
al., 2017). STAT3 increases cell survival by upregulating the expression of the anti-
apoptotic proteins, such as Bcl-2 and Bcl-XL, whereas it promotes cell proliferation 
by upregulating the expression of the proto-oncogene MYC, cyclin D1, cyclin D2 and 
cyclin B (Elinav et al., 2013). The formation of adenomas were prevented by 
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intestinal epithelial cell specific deletion of STAT3 by regulation of cyclin D1, D2 and 
B expression, whereas hyperactivation of STAT3 in gp130Y757F mice promoted 
intestinal tumor growth (Bollrath et al., 2009). Additional evidence for the importance 
of STAT3 in tumor promotion was provided by the intestinal deletion of the STAT3 
inhibitor SOCS3, which increased tumor development, whereas ectopic SOCS3 
expression reduced tumor cell proliferation (Rigby et al., 2007).  
Recently, we found that miR-34a regulates IL6R/STAT3 signaling in colorectal 
carcinogenesis (Rokavec et al., 2014b). miR-34a functions in the context of a 
feedback-loop consisting of IL6R, STAT3 and miR-34a. In this loop, IL6 activates 
STAT3 via IL6R. STAT3 then directly represses the expression of miR-34a. 
Repressed miR-34a cannot target IL6R to down-regulate its expression; as a result 
the IL6R/STAT3 pathway is activated further (Figure 7). The repression of miR-34a 
also induces SNAIL expression which contributes to EMT (Rokavec et al., 2014b). 
 
 
 
1.7 Cancer metastasis 
Cancer metastasis is responsible for 90% of cancer mortality (Elinav et al., 
2013). During tumor progression cancer cells acquire the ability to invade into the 
surrounding tissue, enter into blood vessels and travel to distant organs via the blood 
stream. There the cells penetrate through the vascular wall and form metastatic 
colonies. These subsequently proliferate into clinically detectable metastasis 
(Lambert et al., 2017). This multi-step process of metastasis is summarized in Figure 
8. A large variety of molecular pathways contribute to these complex cellular events 
within tumor cells. In addition, each step of the invasion-metastasis cascade is 
Figure 7. Schematic representation of 
the IL-6R/STAT3/miR-34a feedback 
loop and its potential involvement in 
cancer progression. The activation of 
the loop by IL-6 induces EMT and shifts 
the cellular phenotype towards a 
mesenchymal state that facilitates 
invasion, intravasation, and 
extravasation steps during metastasis. 
Figure and legend are taken from 
(Rokavec et al., 2014b). 
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supported by non-neoplastic stromal cells of the TME (Valastyan and Weinberg, 
2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. The invasion and metastasis cascade. 
Tumor cell metastasis requires distinct features including intravasation, survival in circulation, 
extravasation and colonization at distant organs. Tumor cells are shown in red. The figure is 
taken from (Valastyan and Weinberg, 2011). 
 
The first step of the metastatic process is the epithelial mesenchymal 
transition (EMT) in which cancer cells develop mesenchymal characteristics, such as 
invasion through basal membranes and increased migration. Loss of E-cadherin 
expression is a key step in EMT and E-cadherin expression is regulated by 
transcription factors, such as SNAIL, TWIST, KISS, ZEB1 and ZEB2. These factors 
are activated by pro-inflammatory cytokines TNF, IL1 and IL6 which induce NFκB 
and STAT3 signaling (Sullivan et al., 2009; Yu et al., 2007). For example, it was 
shown that TNF-α signaling stabilizes Snail, which represses E-cadherin and thereby 
promotes metastasis of colon cancer cells (Wu et al., 2009). 
Our results demonstrated STAT3 activation by IL6 directly represses the 
expression of the MIR34A gene via a conserved STAT3-binding site in its first intron 
in human colorectal cancer cells (Rokavec et al., 2014b). Notably, miR-34a directly 
targets and suppresses SNAIL (Kim et al., 2011; Siemens et al., 2011), whereas 
miR-34 family members are directly repressed by SNAIL via direct promoter binding 
in CRC cell lines (Siemens et al., 2011). Another study in breast cancer 
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demonstrated that miR-34a/c suppresses metastasis by inhibiting migration and 
invasion by targeting the Fra-1 oncogene (Yang et al., 2013). 
One of the important suppressors of metastasis is the P53 tumor suppressor, 
which controls the transcription of genes that are involved in canonical metastasis 
pathways, including cell adhesion, invasion, motility, EMT, stemness, anoikis, and 
ECM interactions (Powell et al., 2014). TP53 is mutated or lost in over 50% of all 
human cancers and in some tumors that retain wild-type TP53, defects in the up- or 
downstream of the P53 pathway are detected (Kim and Lozano, 2018). P53 
suppresses metastasis, at least in part, by negatively regulating SNAIL, SLUG and 
TWIST levels via inducing microRNAs of miR-34a and miR-200 family (Powell et al., 
2014). Accordingly, P53-deficient tumors show a poor prognosis (Brosh and Rotter, 
2009). Also, in a mouse model of sporadic colorectal cancer, intestinal epithelial 
specific deletion of Tp53 was shown to promote invasive carcinomas and results in 
lymph node metastases (Schwitalla et al., 2013). In Tp53-deficient mice colon tumors 
expression of Vimentin and Twist was elevated, whereas expression of E-cadherin 
was decreased, indicating that these has undergone EMT (Schwitalla et al., 2013). 
However, many of the mechanisms of p53-mediated suppression of metastasis and 
the role of its downstream targets, such as miR-34a, still remain to be determined. 
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2 Aim of Study 
 
Present study had following aims: 
 
1. Characterization of the role of germ-line Mir34a-deficiency in a mouse model of 
colitis-associated cancer 
 Evaluation of the tumor suppressor function of Mir34a in colitis associated 
carcinogenesis 
 Validation of altered IL6r/Stat3 pathway and its effects in Mir34a-deficient 
colon tumors  
 
2. Characterization of the role of IEC-specific Mir34a-and Tp53-deficiency in a mouse 
model of sporadic colorectal cancer 
 Identification of differentially regulated pathways in Mir34a/Tp53-deficient 
colon tumors  
 Establishment of alternative therapy approaches by inhibition of up-regulated 
Mir34a-targets in Mir34a/Tp53-deficient tumors 
 Validation of the expression of chosen Mir34a-target genes in human primary 
colorectal tumor samples 
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3  Materials and methods 
3.1  Materials 
3.1.1 Chemicals and reagents 
 
Application Chemical Compound Supplier 
In Vivo 
Azoxymethane (AOM) Sigma-Aldrich, St. Louis, MD, USA 
Dextran sulfate sodium salt MP-Biomedicals, California, USA 
MR-16-1 
Chugai-Pharmaceuticals, Shizuoka, 
Japan 
Tiplaxtinin Angene-Chemicals, Nanjing, China 
Isotype-control IgG1 Biolegend, California, USA 
Cell Culture 
Dimethyl-sulfoxide (DMSO) Carl Roth, Karlsruhe, Germany 
Dulbecco's modified eagle’s medium 
(DMEM) 
Invitrogen, Karlsruhe, Germany 
Fetal bovine serum (FBS) 
Gibco®, Life Technologies, Darmstadt,  
Germany 
Hank´s balanced salt solution (HBSS) 
Gibco®, Life Technologies, Darmstadt,  
Germany 
Penicillin-Streptomycin (10,000 U/ml) 
Gibco®, Life Technologies, Darmstadt,  
Germany 
Genotyping 
dNTPs (deoxynucleotides triphosphate) 
Thermo Fisher Scientific, Waltham, MA,  
USA 
Ethidium bromide Carl Roth, Karlsruhe, Germany 
Gene Ruler 100bp plus DNA ladder 
Thermo Fisher Scientific, Waltham, MA,  
USA 
O’Gene Ruler 1kb DNA ladder 
Thermo Fisher Scientific, Waltham, MA,  
USA 
Sea plaque® agarose Lonza, Basel, Switzerland 
Tween® 20 Sigma-Aldrich, St. Louis, MD, USA 
Western- 
Blotting 
Ammonium peroxodisulfate (APS) Carl Roth, Karlsruhe, Germany 
β-mercaptoethanol Sigma-Aldrich, St. Louis, MD, USA 
Bromophenol blue Carl Roth, Karlsruhe, Germany 
Complete mini protease inhibitor cocktail Roche Diagnostics, Mannheim, Germany 
ECL/HRP substrate Merck Millipore, Billerica, MA, USA 
Immobilon-P PVDF, 0.45μm Membrane  Merck Millipore, Billerica, MA, USA 
Methanol Carl Roth, Karlsruhe, Germany 
Nonidet®P40 substitute Sigma-Aldrich, St. Louis, MD, USA 
PageRuler™ Prestained Protein Ladder 
Fermentas, Waltham, Massachusetts,  
USA 
PhosSTOP Phosphatase Inhibitor Cocktail Roche Diagnostics, Mannheim, Germany 
Rotiphorese gel 30 (37,5:1) Carl Roth, Karlsruhe, Germany 
Skim milk powder 
Fluka, Sigma-Aldrich, St.Louis, MD,  
USA 
Sodium dodecyl sulfate (SDS) Carl Roth, Karlsruhe, Germany 
temed (tetramethylethylendiamin,1,2-bis  
(dimethylamino) –ethan) 
Carl Roth, Karlsruhe, Germany 
Tris-base Carl Roth, Karlsruhe, Germany 
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Application Chemical Compound Supplier 
qPCR 
Fast SYBR® Green Master Mix 
Applied Biosystems, Foster City, CA,  
USA 
Fast SYBR Green Master Mix Universal 
RT 
Exiqon A/S, Vedbaek, Denmark 
Histology 
Bovine serum albumin Sigma-Aldrich, St. Louis, MD, USA 
2-(4-Amidinophenyl)-6-indolecarbamidine-
dihydrochloride  
(DAPI) 
Carl Roth, Karlsruhe, Germany 
Hematoxylin Vector Labs, Burlingame, USA 
Hydrogen peroxide Carl Roth, Karlsruhe, Germany 
Paraformaldehyde Santa Cruz, Dallas, Texas, USA 
ProLong Gold antifade Invitrogen, Karlsruhe, Germany 
Target Retrieval Solution, Citrate pH 6 Dako, Agilent Technologies, USA 
Triton X 100 Carl Roth, Karlsruhe, Germany 
Xylol Carl Roth, Karlsruhe, Germany 
Luciferase 
Reporter 
Assay 
Ampicillin Sigma-Aldrich, St. Louis, MD, USA 
Ethidium bromide Carl Roth, Karlsruhe, Germany 
Formamide Sigma-Aldrich, St. Louis, MD, USA 
Gene Ruler 100bp plus DNA ladder 
Thermo Fisher Scientific, Waltham, MA,  
USA 
Hi-Di™ Formamide 
Applied Biosystems, Foster City, CA,  
USA 
HiPerFect Transfection Reagent Qiagen, Hilden, Germany 
LB-Agar (Lennox) Carl Roth, Karlsruhe, Germany 
LB-Medium (Luria/Miller) Carl Roth, Karlsruhe, Germany 
OPTI-MEM®Reduced Serum Medium Life Technologies, Darmstadt, Germany 
Sea plaque® agarose Lonza, Basel, Switzerland 
 
3.1.2 Enzymes 
 
Application Enyzme Supplier 
Genotyping 
HOT FIREPol® DNA Polymerase Solis BioDyne, Estonia 
Proteinase K Sigma-Aldrich, St. Louis, MD, USA 
Cloning 
Pfu DNA Polymerase Thermo Fisher Scientific, USA 
Restriction Endonucleases (AgeI, Pstl) New England BioLabs, Germany 
T4 DNA Ligase Thermo Fisher Scientific, USA 
Cell Culture Trypsin (10x, phenol-red free) Invitrogen, Karlsruhe, Germany 
 
3.1.3 Kits 
 
Application Kit Supplier 
qPCR 
miRCURY LNATM Universal RT microRNA 
PCR  
– Universal cDNA Synthesis Kit II 
Exiqon A/S, Vedbaek, Denmark 
QIAshredder Qiagen, Hilden, Germany 
RNeasy Plus Total RNA Isolation Kit Qiagen, Hilden, Germany 
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Application Kit Supplier 
qPCR Verso cDNA Synthesis Kit 
Thermo Fisher Scientific, Waltham, MA,  
USA 
Western- 
Blotting 
BCA Protein Assay Kit 
Thermo Fisher Scientific, Waltham, MA,  
USA 
Histology 
DAB Substrate Kit Vector Labs, Burlingame, USA 
Streptavidin/Biotin Blocking Kit Vector Labs, Burlingame, USA 
VECTASTAIN Elite ABC HRP Kit Vector Labs, Burlingame, USA 
Cloning 
BigDye® Terminator v3.1 Cycle Sequencing 
Kit 
Life Technologies, Darmstadt, Germany 
DyeEx® 2.0 Spin Kit Qiagen, Hilden, Germany 
QIAquick Gel Extraction Kit Qiagen, Hilden, Germany 
QIAquick PCR Purification Kit Qiagen, Hilden, Germany 
Pure Yield™ Plasmid Midiprep System Promega, Mannheim, Germany 
Luciferase 
Reporter 
Assay 
Dual-Luciferase® Reporter Assay System Promega, Mannheim, Germany 
 
3.1.4 Primary Antibodies 
 
Antibody Species Catalog No. Supplier Application Dilution Source 
BrdU 
Human 
MCA2060 
AbD Serotec; Bio-Rad, 
California,  
USA 
IHC 1:400 Rat 
Mouse 
β-catenin 
Human 
D10A8 
Cell Signaling, Massachusetts, 
USA 
IHC 1:500 Rabbit 
Mouse 
p-Stat3 
Human 
9145 XP 
Cell Signaling, Massachusetts, 
USA 
IHC 1:300 
Rabbit 
Mouse WB 1:1000 
Cleaved-
Caspase-
3 
Mouse 9664 
Cell Signaling, Massachusetts, 
USA 
IHC 1:500 Rabbit 
p-H2AX 
Human 
9718 
Cell Signaling, Massachusetts, 
USA 
IHC 1:480 Rabbit 
Mouse 
F4/80 Mouse MF48000 Invitrogen, Karlsruhe, Germany IHC 1:200 Rat 
CD3 
Human 
A0452 
Dako, Agilent Technologies,  
USA 
IHC 1:200 Rabbit 
Mouse 
Pai-1 
Human 
SC-8979 
Santa Cruz, Dallas, Texas,  
USA 
WB 1:200 Rabbit 
Mouse 
Pai-1 Human MAB10390 Abnova, Taiwan IHC 1:500 Mouse 
β-actin Mouse A2066 
Sigma-Aldrich, St. Louis, MD,  
USA 
WB 1:1000 Rabbit 
α-tubulin 
Human 
Mouse 
T-9026 
Sigma-Aldrich, St. Louis, MD,  
USA 
WB 1:1000 Mouse 
Ki67 Mouse 12202 
Cell Signaling, Massachusetts, 
USA 
IHC 1:500 Rabbit 
IL-6R 
Human 
SC-661 
Santa Cruz, Dallas, Texas,  
USA 
IHC 1:500 
Rabbit 
Mouse WB 1:1000 
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Antibody Species Catalog No. Supplier Application Dilution Source 
Snail Mouse NBP1-19529 
Novus Biologicals, Colarado,  
USA  
WB 1:500 Rabbit 
Snail Mouse 
AP20370PU-
N 
Acris, Rockville, MD, 
 USA 
IHC 1:150 Rabbit 
 
3.1.5 Secondary Antibodies 
 
Antibody 
Catalog 
No. 
Supplier Application Dilution Source 
anti-mouse HRP W4021 
Promega, Mannheim,  
Germany 
WB 1:10000 Goat 
anti-rabbit HRP A0545 
Sigma-Aldrich, St.Louis, MD,  
USA 
WB 1:10000 Goat 
Biotinylated 
E0468 
Dako, Agilent Technologies,  
USA 
IHC 1:500 Rabbit 
Rabbit Anti-Rat 
Biotinylated 
E0432 
Dako, Agilent Technologies,  
USA 
IHC 1:500 Goat 
Goat Anti-Rabbit 
 
3.1.6 Vectors 
 
Name Insert Source  
PGL3-Control-MCS Firefly luciferase Promega, Mannheim, Germany 
PGL3-Pai-1 Mouse Pai-1 3´UTR This study 
PGL3-Pai-1-mutated-SM Mouse Pai-1 3´UTR Mir34a SM mutated This study 
pRL Renilla luciferase Promega, Mannheim, Germany 
 
3.1.7 Oligonucleotides  
3.1.7.1 Oligonucleotides used for genotyping 
 
Name Sequence (5’ - 3’) Product 
miR-34a-Fwd ACCTTGCAGGTGCTCAGAAT Floxed 368 bp 
miR-34a-Rev-2 TGGAGCTAACGGAGTGTGTG Wildtype 510 bp 
miR-34a-Rev-4 CTACCCAAGCTCGACGAAGT Knockout 623 bp 
miR-34a-Rev-8 TGCAGCACTTCTAGGGCAGT   
Tp53-Forward CACAAAAACAGGTTAAACCCAG Floxed 380 bp 
Tp53-Reverse AGCACATAGGAGGCAGAGAC Wildtype 300bp 
Cre-Forward ACCTGAAGATGTTCGCGATTATCT 
Transgene 370 bp 
Cre-Reverse ACCGTCAGTACGTGAGATATCTT 
 
3.1.7.2 Oligonucleotides used for cloning 
 
Name Sequence (5’ -  3’) Application 
Mmu-AgeI-Pai1-Forward ATATACCGGTCAAACCTGCCCCTC 
Cloning 3’-UTR 
Mmu-PstI-Pai1-Reverse TATACTGCAGGGGGAGGGAGGG 
Pai1-clone-seq-Forward1 CCAGTGCAAGTGCAGGTGC 
Sequencing Insert 
Pai1-clone-seq-Reverse1 TATACTGCAGGGGGAGGGAGGG 
 Materials and methods 3 
21 
3.1.7.3 Oligonucleotides used for qPCR 
 
Name Sequence (5’ -  3’) 
Mmu-cMyc-Forward CCTAGTGCTGCATGAGGAGA 
Mmu-cMyc-Reverse TCTTCCTCATCTTCTTGCTCTTC 
Mmu-IL-6-Forward CTCTGGGAAATCGTGGAAAT 
Mmu-IL-6-Reverse CCAGTTTGGTAGCATCCATC 
Mmu-IL-6Rα-Forward GCAAGAATCCTCGTCCATGT 
Mmu-IL-6Rα-Reverse GTGGAGGAGAGGTCGTCTTG 
Mmu-Pai1-Forward GACACCCTCAGCATGTTCATC 
Mmu-Pai1-Reverse AGGGTTGCACTAAACATGTCAG 
Mmu-Cyclophilin-Forward ATGGTCAACCCCACCGTGT 
Mmu-Cyclophilin-Reverse TTCTGCTGTCTTTGGAACTTTGTC 
Mmu-IL-11-Forward GTGGCTGTGGAGAAGCTGTG 
Mmu-IL-11-Reverse GAAGGTCCACGGGAAAGACAC 
Mmu-Snail-Forward CACACGCTGCCTTGTGTCT 
Mmu-Snail-Forward GGTCAGCAAAAGCACGGTT 
Mmu-Vimentin-Forward ATCGACAAGGTGCGCTTCC 
Mmu-Vimentin-Reverse  TTGCCCTGGCCCTTGA 
Mmu-Zeb1-Forward GCTGGCAAGACAACGTGAAAG 
Mmu-Zeb1-Reverse GCCTCAGGATAAATGACGGC 
Mmu-Cldn15-Forward GGCTTCCTGGGCCTCTTTC 
Mmu-Cldn15-Reverse AGCAGCTTGGCCTTCTTGG 
Mmu-Cldn6-Forward  ACTATGCTGCGCCTGCTCTTCTGG 
Mmu-Cldn6-Reverse GATATTCGGAGGGTCCCCGAGA 
Mmu-Muc1-Forward GAGCCAGGACTTCTGGTAGGCT 
Mmu-Muc1-Reverse GGCTTCACCAGGCTTACGTAGT 
Mmu-Muc5-Forward GATCCATCCATCCCATTTCTACC 
Mmu-Muc5-Reverse TTGCTTATCTGACTACCACTTGTTGA  
 
3.1.8 Buffers and Solutions 
Tail lysis buffer: 
• 1.5M Tris/HCL  
• 200 mM NaCl  
• 0.2% SDS  
• 5 mM EDTA 
 
Proteinase K buffer: 
 • 0.1 M Tris (pH 8.5) 
 • 0.2 M NaCl 
 • 5 mM EDTA (pH 8.0) 
 • 0.2% SDS 
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„Vogelstein“ PCR buffer (10X) (Vogelstein and Kinzler, 1999): 
• 166 mM NH4SO4 
• 670 mM Tris (pH 8.8) 
• 67 mM MgCl2 
• 100 mM β-mercapto-ethanol 
 
RIPA buffer (for protein lysis): 
• 1% NP40 
• 0.5% Sodium deoxycholate 
• 0.1% SDS 
• 150 mM NaCl 
• 50 mM TrisHCl (pH 8.0) 
 
Laemmli buffer (2X): 
• 125 mM TrisHCl (pH 6.8) 
• 4% SDS 
• 20% glycerol 
• 0.05% bromophenol blue 
• 10% β-mercaptoethanol 
 
SDS buffer: 
• 50 mM Tris (pH 8.1) 
• 100 mM NaCl 
• 0.5% SDS 
• 5 mM EDTA 
 
10x Running buffer (5L, for SDS-PAGE):  
• 720 g Glycin  
• 150 g Tris base  
• 50 g SDS  
• pH 8.3-8.7  
• 5 L ddH2O  
 
Transfer buffer: 
• 200 mM glycine 
• 20% methanol 
• 25 mM Tris base (pH 8.6) 
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10x TBS-T (5L): 
• 500 ml 1M Tris (pH 8.0) 
• 438.3 g NaCl 
• 50 ml Tween20 
• 5 L ddH2O 
 
PBS (10X): 
• 1.37 M NaCl 
• 27 mM KCl 
• 100 mM Na2HPO4 
• 18 mM KH2PO4 
• Adjust pH to 7.2 wih HCl  
 
In situ hybridization buffer (Schwitalla et al., 2013): 
• 0.9 M NaCl 
• 20 mM Tris/HCl pH7.3 
• 0.01% SDS 
 
3.1.9 Laboratory Equipment 
 
Device Supplier 
5417C table-top centrifuge Eppendorf, Hamburg, Germany 
ABI 3130 genetic analyzer capillary sequencer Applied Biosystems, Foster City, USA 
AxioPlan 2 Microscope System Carl Zeiss, Oberkochen, Germany 
CF40 Imager Kodak, Rochester, New York, USA 
Cell culture flasks, Multiwell plates and Conical 
Tubes 
Corning, New York, USA 
Fisherbrand FT-20E/365 transilluminator Fisher Scientific, Schwerte, Germany 
Forma scientific CO2 water jacketed incubator Thermo Fisher Scientific, Waltham, MA, USA 
GeneAmp® PCR System 9700 Applied Biosystems, Foster City, USA 
Heraeus Megafuge 1.0R Thermo Fisher Scientific, Waltham, MA, USA 
KAPPA ImageBase software KAPPA opto-electronics, Gleichen, Germany 
LSM 700 Laser Scanning Confocal Microscope Carl Zeiss, Oberkochen, Germany 
Mini-PROTEAN®-electrophoresis system Bio-Rad, Munich, Germany 
MultiImage Light Cabinet Alpha Innotech, Johannesburg, South Africa 
ND 1000 NanoDrop Spectrophotometer NanoDrop products, Wilmington, DE, USA 
Neubauer counting chamber Carl Roth, Karlsruhe, Germany 
Polytron PT 1200E tissue homogenizer Kinematica,  Luzern, Switzerland 
Orion II luminometer Berthold Technologies, Bad Wildbad, Germany 
Varioskan Flash Multimode Reader Thermo Fisher Scientific, Waltham, MA, USA 
Waterbath Memmert GmbH, Schwabach, Germany 
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3.2 Methods 
3.2.1  Mouse models 
 
Mir34aFL/FL and Mir34a-/- mice 
The generation of Mir34a-/- mice with a C57BL6/SV129 back-ground was performed 
by Dr. Lodygin and has been described in our publication (Rokavec et al. 2014). 
Gene specific deletions were generated by using homologous recombination with a 
vector containing Mir34a or Mir34b/c sequences flanked by loxP sites and an intronic 
Neomycin resistance (Neo) cassette flanked frt sites individually. The Neo cassette 
was removed by crossing with flp-mice and germ-line Mir34a knock-out mice were 
generated by crossing with CMVCre mice. When Mir34aFL/FL mice were crossed to a 
mice line expressing a Cre recombinase under the control of a promoter of interest, 
Mir34a expression was stopped. In order to get Mir34aFL/FL mice in FvB background, 
we performed 5 backcrosses to FvB mice (5 crosses to FvB mice theoretically 
correspond to at least 96% of FvB background). 
 
Tp53FL/FL mice 
In Tp53FL/FL mice exons 2-10 of the Tp53 gene are flanked by loxP sites (Jonkers, 
Meuwissen et al. 2001). Cre mediated recombination under the control of a promoter 
of interest generates a Tp53 null-allele in targeted tissue. 
 
Villin-Cre mice 
This mouse line harbors the Cre recombinase under control of the mouse Villin 
promoter (Madison, Dunbar et al. 2002). Cre recombinase recombines genes flanked 
by loxP sequences. Crossing of mice of the Villin-Cre line with a mouse containing a 
loxP-flanked gene of interest “floxed”, leads to tissue-specific deletion of the targeted 
sequence. 
 
Genotype Background Source 
Mir34aFL/FL C57BL/6J and FvB This work 
Mir34a-/- C57BL/6J This work 
Tp53FL/FL FvB The Jackson Laboratory 
Mir34aFL/FL/Tp53FL/FL FvB This work 
Villin-Cre C57BL/6J and FvB The Jackson Laboratory 
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Step Temperature Time
Initiation 95°C 15 min.
95°C 30 sec.
59°C 30 sec.
72°C 40 sec.
Final elongation 72°C 3 min.
PCR-conditions
37 Cycles
Step Temperature Time
Initiation 94°C 10 min.
94°C 30 sec.
58°C 30 sec.
72°C 30 sec.
Final elongation 72°C 7 min.
PCR-conditions
35 Cycles
3.2.2 Genotyping 
 
Mice tails were lysed overnight at 60°C in 95 μl tail lysis buffer supplemented with 5 
μl Proteinase K (Qiagen). The enzymatic digestion was stopped by heat inactivation 
at 95°C for 10 min. Samples were diluted 1:10 with distilled water and centrifuged for 
5 min at 13200 rpm. Supernatants were used for polymerase chain reaction (PCR). 
 
Genotyping PCR conditions for each gene are indicated in below: 
 
Mir34a genotyping: 
Master mix and thermocycler conditions:                                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P53 genotyping: 
 
Master mix and thermocycler conditions:  
 
 
 
  
Component Volume (μl)
 Invitrogen PCR Buffer 
(10X)
2
50 mM MgCl2 1
10 mM dNTPs 0.4
10uM p53-Fwd.-Primer 0.5
10uM p53-Rev.-Primer 0.5
Hot Firepol Taq 
Polymerase
0.15
dH2O 13.95
Genomic DNA 1.5
Total 20
Component Volume (μl)
 Vogelstein PCR Buffer 
(10X)
2.5
10 mM dNTPs 1
10 μM 34a-Fwd-Primer 2
10 μM 34a-Rev.2-Primer 1
10 μM 34a-Rev.4-Primer 1.5
10 μM 34a-Rev.8-Primer 0.5
Hot Firepol Taq 
Polymerase
0.5
dH2O 16.5
Genomic DNA 1
Total 25
 Materials and methods 3 
26 
Step Temperature Time
Initiation 94°C 10 min.
94°C 30 sec.
58°C 30 sec.
72°C 30 sec.
Final elongation 72°C 7 min.
PCR-conditions
35 Cycles
Villin-Cre genotyping: 
 
Master mix and thermocycler conditions: 
 
 
 
 
All genotyping primers are listed under section 3.1.7.1. 
 
3.2.3  AOM/DSS and 6XAOM administration 
 
To induce colitis-associated carcinogenesis mice at the age of 6 to 10 weeks 
were intraperitoneally (i.p.) injected with 10 mg/kg Azoxymethane (AOM, Sigma) 
once at day 0 and once at day 21 of the model. Five days after first AOM injection, 
mice received  2% dextran sulfate sodium salt (DSS, MP-Biomedicals) in the drinking 
water for 5 days, followed by 16 days of regular water (first and second cycles). 
During the third cycle, no AOM and only 2% DSS were administered. At day 110, 
mice were sacrificed. 
For sporadic colorectal carcinogenesis model, mice were injected i.p. with 10 
mg/kg AOM, six times in weekly intervals and on week 16 all mice were sacrificed. 
 
3.2.4 Treatment with MR16-1 and Tiplaxtinin 
 
For blocking IL6R activity mice were i.p. injected weekly with 1 mg antibody 
against mouse IL6R (MR16-1, kindly provided by Chugai Pharmaceuticals) or, as 
isotype control, 1 mg Rat IgG1 (GoInVivo-Biolegend). The Pai-1 inhibitor Tiplaxtinin 
was purchased from Angene chemicals (Nanjing, Jiangsu Province China). 
Tiplaxtinin supplemented food (1 g tiplaxtinin/kg chow) was given from week 9 to 16 
to mice and prepared by Ssniff-Special Diets (Soest, Germany). 
All animal protocols were approved by the local authorities (Regierung von 
Oberbayern, AZ: 55.2-1-54-2532-201-2014). 
 
Component Volume (μl)
 Vogelstein PCR Buffer 
(10X)
2.5
10 mM dNTPs 2
10 μM 370-Fwd-Primer 1.2
10 μM 370-Rev.-Primer 1.2
Hot Firepol Taq 
Polymerase
0.2
dH2O 15.9
Genomic DNA 2
Total 25
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3.2.5  Intestinal epithelial cell (IEC) isolation 
 
For IEC isolation, intestine were opened longitudinally and chopped into small 
pieces and incubated in 1xHBSS supplemented with 30 mM EDTA for 10 min on a 
rocking-platform at 37°C. The tube was vortexed for 30 seconds and placed, 
incubated on ice. The supernatant including detached epithelial cells was transferred 
into a new falcon tube and centrifuged at 1500 rpm for 10 min at 4 °C. The pelleted 
epithelial cell were washed with PBS, transferred to Eppendorf tubes and centrifuged 
at 5000 rpm for 5 min at 4°C. The supernatants were discarded and the cell pellets 
were snap frozen in liquid nitrogen and stored at -80°C. 
 
3.2.6  Bromodeoxyuridine (BrdU) injection and sacrifice of the mice 
 
BrdU is incorporated in the DNA instead of thymidine during cell proliferation. 
The incorporation of BrdU by proliferating cells was detected by 
immunohistochemistry. 90 minutes before sacrifice, mice were injected i.p. with 75 
mg/kg BrdU (Sigma) that was dissolved in PBS.  
 
3.3 Human samples 
Formalin-fixed, paraffin-embedded (FFPE) colon cancer samples of 61 patients 
who underwent surgical tumor resection at the Ludwig-Maximilians University of 
Munich (LMU) between 1994 and 2005 were used for PAI-1 IHC. All tumors were 
located on the right side of the colon. Tissue microarrays (TMAs) were generated 
with 6 representative 1 mm cores of each case. 5 µm TMA sections were prepared, 
deparaffinized and stained with anti-PAI-1 (Abnova) mouse monoclonal antibody on 
a Ventana Benchmark XT Autostainer with UltraView Universal DAB and alkaline 
phosphatase detection kits (Ventana Medical Systems). All procedures involving 
human tumor biopsies were performed with the approval of the ethics committee of 
the Ludwig-Maximilians University Munich.  
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3.4  Histology 
3.4.1 Haematoxylin & Eosin (H&E) staining 
For H&E staining, FFPE tissues were cut in to 2 μm thick slides. H&E staining 
were performed by an automated slide staining system according to standard 
protocols.  
 
3.4.2 Fluorescence in situ hybridization (FISH) 
 
For FISH, the universal eubacteria probe (EUB338) and negative control 
probe (NON338) were employed to visualize intestinal bacteria cells as described 
(Schwitalla et al., 2013). The 5’-FITC-labeled EUB338 DNA probe (5’-
GCTGCCTCCCGTAGGAGT-3’) and 5’-Cy3-labeled NON338 DNA probe (5’-
CGACGGAGGGCATCCTCA-3’) were synthesized by Metabion. Freshly prepared 3 
μm paraffin sections were deparaffinized in Xylol and incubated for 10 minutes in 
100% EtOH. The bacterial probes were diluted to a final concentration of 1 ng/ μL in 
pre-warmed hybridization buffer (described under section 3.1.8) and the hybridization 
was performed at 50°C overnight. Afterwards, the hybridized tissue sections were 
washed 3 times for 15 minutes in pre-warmed hybridization buffer, rinsed in distilled 
water and mounted with DAPI containing medium. 
 
3.4.3 Immunohistochemical analysis 
 
For each immunohistochemical staining, 2 μm thick FFPE slides were used. 
Tissue sections were deparaffinized. After dehydration, for antigen retrieval, the 
tissue sections were boiled for 20 minutes in a microwave in antigen unmasking 
solution (Dako, citrate, pH 6). After cooling down, to quench endogenous tissue 
peroxidases, slides were treated for 10 minutes with 3% H2O2/PBS solution. Next, 
tissue sections were washed with PBS and blocked for 30 minutes using 3% 
BSA/PBS supplemented with avidin-block (2 drops per ml, Vector) to block unspecific 
binding sites for antibodies at room temperature. Then, tissue sections were 
incubated with the primary antibody against the epitope of interest diluted in 3% 
BSA/PBS plus biotin-block (2 drops per ml, Vector Laboratories) over night at 4 °C 
(respective dilutions are indicated under section 3.1.4). The next day, tissue sections 
were washed twice for 5 minutes with PBS. The secondary antibody conjugated with 
Biotin (Vector Laboratories) was diluted 1:500 in 3% BSA/PBS for incubation with the 
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tissue sections for 30 min. An ABC complex solution consisting of avidin 
dehydrogenase and biotinylated horseradish peroxidase (Vector Laboratories) was 
prepared by adding 2 drops of each solution A & B to 5 mL PBS and incubated for 30 
min at 4°C prior to use. After washing with PBS the tissue slides were incubated for 
30 min with ABC complex solution. For the DAB (3,3’-diaminobenzidine) color 
reaction, 2 drops of buffer were mixed with 4 drops of DAB and 2 drops of peroxidase 
(DAB Kit, Vector Laboratories) in 5 ml of distilled water. The staining solution was 
applied to the tissue slides until the staining for the target of interest was appropriate. 
The reaction was stopped in distilled water. Nuclei were counterstained with 
hematoxylin for 1 minute, washed with distilled water and dehydrated.   
 
3.5  RNA/DNA analysis 
3.5.1 RNA Isolation 
 
Total RNA from animal tissues was isolated with RNeasy Plus Total RNA 
Isolation Kit (Qiagen). Tissues were lysed in 600 μl of RTL buffer supplemented with 
1% β-mercaptoethanol by using a tissue homogenizer (Polytron PT 1200 E). Next, 
tissue lysates were passed through QIAshredder columns (Qiagen). The flow-
through was then used for RNA isolation according to manufacturer’s protocol. RNA 
was eluted in RNase-free water. The amount and quality of the isolated RNA was 
measured by NanoDrop spectrophotometer (Thermo Fisher Scientific). RNA samples 
were stored in -80°C until use. 
 
3.5.2 cDNA synthesis 
 
250 ng-1 μg of total RNA was used to generate cDNA by using Verso cDNA 
synthesis kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. 
Resulting cDNA samples were stored at -20°C. 
 
3.5.3 Quantitative real time PCR (qPCR) analysis 
 
  Analysis of mRNA expression was carried out by using Fast SYBR Green 
Master Mix (Applied Biosystems) on a LightCycler 480 (Roche). The reaction mix per 
well contained 7,5 μl of SYBR-Green MasterMix, 5,5 μl of distilled water, 1 μl of 
cDNA and 1 μl of the respective primer mix (containing 20 mM each: forward and 
reverse primer). Results are represented as fold induction using the ΔΔCt method 
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(Pfaffl, 2001) with the control set to 1 as described before (Menssen et al., 2007). 
The individual mRNA levels were normalized to Cyclophilin expression. Primers used 
for qPCR are listed under section 3.1.7.3. 
 
3.5.4 RNA sequencing 
 
Total RNA from murine tumors was isolated as described above. RNA profiling 
was done in triplicates (3 RNA samples per genotype; each tumor RNA sample 
represented a pool of 3 tumors isolated from the same mouse). Random primed 
cDNA libraries were generated and sequenced using the HiSeq2500 (Illumina) 
platform by GATC (Konstanz, Germany). Each sample was covered by at least 30 
million single reads of 50 bp length. The raw reads were cleaned by trimming of 
adaptor sequences and low quality sequences with average quality scores less than 
20. Trimmed reads were mapped to the mm10 mouse reference genome and 
processed using the RNA-seq module of the CLC Genomics Workbench software 
(Qiagen Bioinformatics) with default settings. Expression (reads) was normalized by 
using the RUV-method (Risso et al., 2014). Mice displayed increase in the degree of 
tumor aggressiveness (tumor number/size/invasiveness) from wt over Mir34aΔIEC and 
p53ΔIEC to Mir34aΔIECp53ΔIEC mice. Therefore, differentially expressed genes were 
determined by a t-test for trend based on Spearman correlation between expression 
and genotypes ranked in the order: wt, Mir34aΔIEC, p53ΔIEC, Mir34aΔIECp53ΔIEC.  For 
principal component analyzes the ClustVis tool was used (Metsalu and Vilo, 2015). 
Gene Set Enrichment Analyses (GSEA) were performed using the GSEA software 
(Broad Institute, Boston, USA) and data from the molecular signature database 
(MSigDB) (Subramanian et al., 2005). The significance of enrichments is presented 
by normalized enrichment scores in false discovery rate (FDR) adjusted q-values. 
Expression profiling data was deposited in the Gene Expression Omnibus website 
(Accession No. GSE99452). 
 
3.5.5 Analysis of expression and methylation data from online patient data 
sets   
 
mRNA expression, methylation (beta-values determined by 450K BeadChip 
arrays (Illumina)), and clinical data of Colon adenocarcinoma (COAD) and rectal 
adenocarcinoma (READ) cohorts were obtained from the TCGA data portal (tcga-
data.nci.nih.gov/tcga/tcgaDownload.jsp) (Cancer Genome Atlas, 2012), MD 
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Anderson standardized data browser 
(http://bioinformatics.mdanderson.org/TCGA/databrowser/), and the UCSC cancer 
browser (https://genome-cancer.ucsc.edu). Tp53 mutation data was obtained from 
cBIO and OASIS (Cerami et al., 2012; Hafi et al., 2016). For representation of RNA-
Seq. results the Expectation-Maximization (RSEM) normalized expression values 
from the Illumina RNASeqV2 (genes) datasets were used. Methylation of miR-34a 
was determined by averaging the methylation levels of the 7 CG sites (450k 
BeadChip probes cg04413644, cg04112567, cg03521358, cg06658816, 
cg02924110, cg24167422, and cg12385729) located in the CpG island in the 
miR34a promoter (Lodygin et al., 2008). For binary classification (high/low 
methylation), the mean methylation was used as a cut-off. The CMS classification of 
TCGA samples was obtained from Synapse (www.synapse.org). Expression and 
clinical data of GSE39582, GSE37892, GSE17536, and GSE14333 datasets was 
down- loaded from NCBI GEO (www.ncbi.nlm.nih.gov/geo). The association of PAI-1 
expression with nodal status or metastasis was calculated by Student’s t-test. The 
significance of Kaplan-Meier survival curves was calculated with a log-rank test. For 
binary classification of cases (high/low expression), receiver operated characteristics 
(ROC) curve analysis were used to determine optimal cut-off values using the Cut-off 
Finder tool (http://molpath.charite.de/cutoff/assign.jsp). 
 
3.6 Protein analysis 
3.6.1 Preparation of protein lysates 
 
For protein extraction, tissues were lysed by mechanical homogenization with 
a micro-pistil in 200 μl ice-cold protein lysis buffer Lysates were incubated for 10 
minutes on ice, centrifuged at 13200 rpm at 4°C for 10 minutes to pellet cell debris. 
Protein containing supernatants were stored at -80°C. 
 
3.6.2 Western blot analysis 
 
For western blotting, protein concentration was measured with BCA Protein 
Assay Kit (Thermo Fisher Scientific) by Varioskan Flash Multimode Reader (Thermo 
Scientific) using the SkanIt RE for Varioskan 2.4.3 software (Thermo Scientific). 30-
40 μg of protein were adjusted to a volume of 24 μl by filling up with protein lysis 
buffer, and 8 μl of 4x Laemmli buffer was added. The samples were boiled at 95°C 
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for 5 minutes, cooled down on ice, briefly centrifuged and loaded onto the gel. The 
gel was run at 100 volt in 1x running buffer. Proteins were transferred on Immobilon 
PVDF membranes (Millipore) by using Mini-Protean-electrophoresis system (Bio-
Rad) in 1x transfer buffer 90 minutes at 350 mA. After the transfer, membrane was 
washed in TBS-Tween 20 (TBST) and incubated for 30 minutes at room temperature 
with 3% (w/v) skim milk (Roth)-TBST to block unspecific binding of antibody. Then, 
the membrane was incubated with a primary antibody (listed under section 3.1.4) at 
4°C, overnight. Next day, membrane was washed 3 times, 10 minutes with TBST.  
HRP-coupled secondary antibody (listed under section 3.1.5) of choice was applied 
onto the membrane at room temperature for 1 hour. Then, membrane was washed 3 
times for 10 minutes with TBST. For detection, ECL solution (Millipore) was applied 
to the membrane for 5 minutes and signals were recorded with a 440CF imaging 
system (Kodak). 
 
3.7 Cloning 
3.7.1 Cloning of Pai-1 3´-UTR sequence into PGL3 plasmid 
 
The predicted wild-type and mutated miR-34a seed match sequence in 3´UTR 
of mouse Pai-1 that contains Age1 and Pst1 restriction sites on 5´ and 3´ ends 
respectively were generated by annealing synthetic oligos and inserted into pGL3-
control-MCS vector (downstream of a firefly luciferase ORF), and verified by 
sequencing. 
 
3.7.2 Digestion 
 
Digestion of the vector and the insert were performed by using manufacturer´s 
protocol (New England Biolabs) at 37°C for 2 hours. The restriction of the plasmid 
was confirmed on a 1% agarose gel. The linearized plasmid fragment was eluted 
from the agarose gel using a Gel Extraction Kit (Qiagen). 
 
3.7.3 Ligation 
 
Ligation of DNA constructs was performed overnight at 4°C by using 1 U of T4 
Ligase (Invitrogen) in a total volume of 20 μL using a vector-insert molecular ratio of 
1:3. 
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3.7.4 Transformation 
 
In order to transform Pgl3-Pai-1 vector that harbors ampicillin resistance, 
competent bacteria E. coli XL-1 blue strain was used. A 200 μL aliqot of competent 
bacteria was thawed on ice for 5 minutes and approximately 100 ng of DNA plasmid 
was added on and incubated 30 minutes on ice. The heat shock was performed for 
90 seconds at 42 °C and then transformed bacteria were placed on ice for additional 
2 minutes. 800 μL of antibiotic-free LB medium was added on and then bacteria were 
incubated for 1h at 37 °C shaking before the bacterial culture was plated on LB-Agar 
plates including ampicillin. The plates were incubated overnight at 37 °C. 
 
3.7.5 Isolation of plasmid DNA from bacteria 
 
Single colonies from transformed bacteria on LB-agar plates were inoculated 
either in 2 ml or 150 ml of LB-broth containing 100 μg/ml ampicillin and incubated 
overnight while at 37 °C (shaking at 225 rpm). In order to isolate a plasmid from the 
bacterial culture Pure Yield™ Plasmid Midiprep System (Promega) was used 
according to the manufacturer´s protocol for DNA purification. The DNA 
concentration was determined by using NanoDrop (Thermo Scientific).   
 
3.7.6 Colony PCR 
 
To identify the orientation of DNA inserts colony PCR was performed. For this 
purpose, 20 μl of a PCR master mix containing vector and/or insert specific primers, 
dNTPs, 10x Vogelstein PCR buffer and FIREPol® DNA polymerase (Solis BioDyne) 
was prepared. Single colonies were picked from the LB-agar plate and transferred 
into corresponding PCR tube. The PCR cycling conditions were as the following: 
95°C for 5 minutes, followed by 25 cycles of 95°C for 20 seconds, 55°C for 30 
seconds and 72°C for X minute/s (1 minute per 1 kb length of the expected PCR 
product), and then another 72°C for 7 minutes. PCR fragment length was assessed 
by an agarose gel electrophoresis (percentage of the gel was prepared according to 
the expected product size).  
3.7.7 Sequencing 
 
To verify whether desired DNA sequence was introduced into Pgl3-plasmid, 
DNA sequencing was performed according to the BigDye Terminator v1.1 Cycle 
Sequencing Kit´s protocol (Life Technologies). Briefly, a master mix was prepared 
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containing Big Dye Terminator V1.1, 5×Sequencing buffer, primer (10 μM) and 
plasmid (1 μg/ml). Then PCR program was run by 15 cycles of each 10 seconds at 
96°C and 90 seconds at 60°C. Later, the DyeEx 2.0 Spin Kit (Qiagen) was used 
according to the manufacturer’s protocol with a 5417C centrifuge (Eppendorf). After 
that, purified DNA was mixed with Hi-Di Formamide (Applied Biosystems), and 
loaded into to ABI3130 genetic analyzer capillary sequencer (Applied Biosystems) for 
sequencing. Data was analyzed by the 3130 Data Collection Software v3.0 and the 
sequencing analysis software 5.2 (Applied Biosystems).  
3.8  Cell culture 
3.8.1 Cultivation 
 
H1299 cancer cell line was cultured in Dulbecco's modified Eagle’s medium 
(DMEM, Invitrogen) with 10% fetal bovine serum (Invitrogen), penicillin (100U/ml), 
0.1mg/ml streptomycin (Gibco) at 5% CO2, 37°C. CT26 cell line was cultured in RPMI 
1640 medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen), 
penicillin (100U/ml), 0.1mg/ml streptomycin (Gibco) at 5% CO2, 37°C. CT26 cells 
were transfected with pre-miR-34a (Ambion, PM11030) or with a negative control 
(Ambion, neg. control #1) for 48 hours by using Lipofectamine 2000 transfection 
reagent (Invitrogen).  
 
3.8.2 Transfection of oligonucleotides and vector constructs 
 
Transfections of oligonucleotides and vector constructs were carried out using 
freshly trypsinized and seeded cells in the medium and cell-culturing format of 
choice, preferentially into a six- or twelve-well format, 24 hours before transfection. 
For transfection of oligonucleotides or plasmid DNA into the cells, HiPerFect 
(Qiagen) transfection reagent was used. For six-well format, the transfection reagent 
mix contained 100 μl Opti-MEM (Invitrogen), 10 μl HiPerFect (Qiagen) and 10 μl of 
the respective oligonucleotide (10 μM) (Ambion – Applied Biosystems, final 
concentration (100 nM)) or 4 μg of the plasmid DNA. Transfection reagent added last 
to the mix and incubated 15 minutes before drop-wise application of the mix on to the 
cells. 48 hours later, cells were harvested for the luciferase reporter assay. 
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3.9  Luciferase assay 
For luciferase assays, H1299 cells were seeded in 12-well format dishes at 
3x104 cells/well, and transfected after 24 hours with 100 ng of the respective firefly 
luciferase reporter plasmid, 20 ng of Renilla reporter plasmid as a normalization 
control and 25 nM of pre-miR-34a (Ambion, PM11030) or a negative control 
oligonucleotide (Ambion, neg. control #1) by using HiPerfect transfection reagent 
(Qiagen). After 48 hours a Dual Luciferase Reporter assay (Promega) was performed 
according to manufacturer’s instructions. Fluorescence intensities were measured 
with an Orion II luminometer (Berthold) in 96-well format and analyzed with the 
SIMPLICITY software package (DLR). Primers used for cloning and sequencing are 
given under section 3.1.7.2. 
 
3.10  Statistics 
The association between miR-34a methylation/TP53 mutation and distant 
metastasis was calculated using the Chi-square test for trend. The association 
between miR-34a methylation/TP53 mutation and survival was calculated using the 
log-rank test for trend. The association of PAI-1 expression with nodal status or 
metastasis was calculated by Student’s t-test. Survival curve of mice was analyzed 
by Kaplan-Meier method with a log-rank test. Results were expressed as mean ± 
SEM. Differences were analysed by a two tailed Student’s t-test. Calculations were 
performed using Prism5 (Graph Pad Software Inc.) and P-values ≤ .05 were 
considered as significant, P* ≤ .05; P** ≤ .01; P*** ≤ .001. 
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4 Results 
4.1 Germ-line Mir34a-deficiency increases tumor load and invasion in a colitis 
associated model of colorectal carcinogenesis 
Previously, we have shown that miR-34a plays an important role in intestinal 
epithelial cells in response to IL6 mediated inflammation (Rokavec et al., 2014b). 
Accordingly, miR-34a functions in the context of a positive feedback-loop consisting 
of IL6R, STAT3 and miR-34a where IL6 activates STAT3 via IL6R, STAT3 then 
directly represses the expression of miR-34a, which targets and down-regulates IL-
6R. Furthermore, results by Dr. Rokavec and Dr. Li, indicated that IL6 effectively 
induces EMT in colorectal cancer (CRC) cell lines, which is mediated by the direct 
repression of miR-34a by STAT3. Moreover, CRC cell lines with mesenchymal and 
therefore invasive features consistently showed up-regulation of this feedback loop. 
Similarly, primary colorectal tumors that develop distant metastasis displayed an 
association with activation of the IL6R/STAT3/miR-34a feed-back loop.  
 
In order to analyze the relevance of an IL6R/STAT3/miR-34a feedback loop in 
an autochthonous colorectal tumor model, the well-established 
azoxymethane/dextran sodium sulfate (AOM/DSS) model was employed (Neufert et 
al., 2007), which closely recapitulates human colitis-associated cancer (CAC). Since 
miR-34a was expressed more than approximately 1000-fold higher levels than miR-
34b and miR-34c in intestinal epithelia and approximately 180-fold higher in intestinal 
tumors (data not shown), I focused on the role of miR-34a in CAC. Compared to wt 
mice, expression of Mir34a was markedly elevated in colon tissue of mice with 
intestinal cell–specific Stat3 deletion (Stat3ΔIEC) (Figure 9A). DSS treatment of 
Mir34aF/F mice for 5 days resulted in decreased expression of Mir34a in colon 
epithelial cells accompanied by an induction of IL6 expression in colon tissue (Figure 
9B-C). Therefore, Mir34a is also repressed by inflammatory signaling in vivo, which is 
known to involve Stat3 activation (Grivennikov et al., 2010).  
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Figure 9. Altered expression of Mir34a and IL6 after short-DSS treatment. 
(A) Expression of Mir34a in colon tissue of wt and Stat3ΔIEC mice. cDNAs for this experiment 
were provided by Prof. Florian Greten and Paul Ziegler. (B) Expression of IL6 mRNA in colon 
tissue of Mir34aF/F mice after 5 days of DSS treatment. (C) Expression of Mir34a in colon 
epithelial cells of Mir34aF/F mice after 5 days of DSS treatment. Mean values ± SEM are 
provided. *P < 0.05.  
 
In order to investigate the role of Mir34a in AOM/DSS-induced carcinogenesis, 
Mir34a-deficient (Mir34a-/-) mice were employed which had been generated in the 
Hermeking lab. previously. Mir34a-/- mice did not display an obvious phenotype or 
any spontaneous tumor formation and showed normal Mendelian inheritance (data 
not shown). Upon AOM/DSS treatment, the incidence and size of tumors were 
significantly enhanced in Mir34a-/- mice compared to Mir34aF/F mice (Figure 10A-C). 
Moreover, Mir34a-deficient colon tumors revealed increased cell proliferation and 
decreased apoptosis compared to Mir34a-proficient tumors (Figure 10D-E). 
Importantly, approximately 70% of Mir34a-/- mice displayed invasive tumors that 
penetrated through the muscularis mucosa, whereas none of the tumors from 
Mir34aF/F mice showed invasion (Figure 10F-G). Loss of TP53 has been suggested to 
be essential for colon tumor invasion (Fearon and Vogelstein, 1990) and was 
recently linked to activation of NF-κB and Stat3 (Schwitalla et al., 2013), which also 
comprise important signaling nodes in CAC (Bollrath et al., 2009; Grivennikov et al., 
2009). Sequencing the entire Tp53 coding region in tumors from 6 Mir34aF/F and 10 
Mir34a-/- mice did not reveal any mutations in either genotype. Therefore, the deletion 
of Mir34a presumably substituted for the inactivation of Tp53 as a requirement for 
invasiveness. 
A B C 
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Figure 10. Deletion of Mir34a facilitates tumor invasion after AOM/DSS treatment. 
(A) Schematic overview of the AOM/DSS treatment to induce CAC. Injections (i.p.) of 10 
mg/kg AOM were performed once at day 0 and once at day 21. Five days after AOM 
injection, mice received 2% DSS in the drinking water for 5 days, followed by 16 days of 
regular water. During the third cycle, no AOM and only 2% DSS were administered. At day 
110, mice were sacrificed. (B) Tumor incidence in indicated mice (n ≥ 10 mice for each 
genotype). (C) Mean tumor size in indicated mice (n ≥ 5 mice for each genotype). (D) Tumor 
cell proliferation was determined by BrdU incorporation. Percentage of proliferation indicates 
BrdU-positive cells (n ≥ 10 tumors of each genotype). (E) Tumor cell apoptosis was 
determined by detection of cleaved caspase-3. Percentage of positive cells is indicated (n ≥ 
10 tumors of each genotype). (F) H&E-stained sections of colons from Mir34aF/F and Mir34a-/- 
mice with arrows indicating magnified areas showing tumor morphology and representative 
invasive colon carcinoma in Mir34a-/- mice. Scale bars: 500 μm. (G) Percentage of mice 
showing invasive tumors for indicated genotypes. Number of mice with invasive tumors/total 
number of mice for each genotype is indicated above the bars. Mean values ± SEM are 
provided. *P < 0.05; **P <0 .01; ***P <0 .001. 
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4.2  Mir34a-loss activates IL6R/Stat3 signaling in colitis-associated tumors 
and allows invasion 
In order to show Mir34a-deficiency regulates IL6R/Stat3 axis, Mir34a 
expression levels were checked after siRNA-mediated knock-down of Stat3 in the 
murine colorectal cancer cell line CMT93, which is known to expresses constitutively 
active phospho-Stat3 (pStat3). In line with this hypothesis, Mir34a expression was 
elevated after Stat3 knock-down (Figure 11A). Furthermore, Mir34a-/- mice showed 
increased phosphorylation of Stat3 and elevated expression of IL6R in tumor cells 
compared to Mir34aF/F mice (Figure 11B-C). Also, the levels of the EMT inducer and 
Mir34a target SNAIL was markedly increased in Mir34a-/- mice, suggesting that tumor 
cells in these mice underwent EMT (Figure 11B-C). Finally, Mir34a-/- tumors 
displayed increased Stat3 phosphorylation and expressed higher levels of IL6R, 
SNAIL and ZEB1 protein and RNA compared to Mir34aF/F tumors (Figure 11D-E).  
Taken together, Mir34a-loss activates IL6R/Stat3 signaling in colitis-associated 
tumors and allows EMT, invasion and metastasis. 
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Figure 11. The tumors of Mir34a-/- mice show characteristics of EMT and enhanced 
IL6R/STAT3 signaling. (A) Expression of mature miR-34a and Stat3 in mouse rectal cancer 
cell line CMT93 transfected with control or Stat3 siRNA. cDNA samples from CMT93 cells 
were generated by Paul Ziegler and provided us by Prof. Florian Greten.  
(B and C) Immunohistochemical analysis of p-STAT3, IL6R, and SNAIL in tumors of 
Mir34aF/F and Mir34a-/- mice. Yellow and green arrows indicate tumor and stoma cells, 
respectively. Scale bars: 50 μm; 20 μm (insets). Bar charts (C) show the percentage of 
positive tumor cells (index; p-STAT3 and SNAIL) or expression score (IL6R) determined (n 
≥10 tumors from each genotype). (D) Western blot analysis of indicated proteins in lysates 
prepared from tumors of Mir34aF/F and Mir34a-/- mice (n = 5 from each genotype). Relative 
densitometric quantifications of indicated proteins are shown in lower panel. (E) qPCR 
analysis of indicated mRNAs in tumors of Mir34aF/F and Mir34a-/- mice (n = 3 from each 
genotype). A,C,E: Bars represent mean values ± SEM. *P <0 .05; **P < 0.01; ***P <0 .001. 
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4.3  Mir34a and Tp53 cooperatively suppress colorectal tumorigenesis 
In this second part of the study, cooperative effects of Mir34a and Tp53 were 
investigated and characterized in a sporadic colon cancer model. 
TP53 and MIR34a are frequently inactivated by mutation or CpG methylation in 
CRC (Fearon and Vogelstein, 1990; Siemens et al., 2013). So far it has not been 
determined whether the combined inactivation of these genes was clinically relevant. 
Therefore correlation between TP53 mutation and MIR34A CpG methylation was 
analyzed. In 208 CRC samples represented within the TCGA database, patients with 
TP53 mutated and MIR34A CpG methylated colorectal tumors had poorest survival 
(Figure 12A). Moreover, patients with distant metastasis (M1) had significantly higher 
numbers of primary colorectal tumors with simultaneous MIR34a methylation and 
TP53 mutation than patients without distant metastasis (M0) (Figure 12B). Therefore, 
the combined inactivation of MIR34a and TP53 is associated with a poor prognosis 
and distant metastasis in CRC patients.  
 
 
Figure 12. miR-34a methylation and TP53 mutation are associated with poor survival 
and distant metastasis in CRC patients.  
Association of miR-34a methylation and TP53 mutation with (A) overall survival in CRC 
patients (n=177) and (B) distant metastasis in CRC patients (n=207). Significance was 
calculated by the (A) log-rank test for trend and (B) by the Chi-square test for trend. MCpG: 
DNA methylation. P values are provided as *P < 0.05.  Figures (A-B) were generated by Dr. 
Matjaz Rokavec. 
 
As expected, MIR34A methylation and expression showed a significant, 
negative correlation in these samples (Figure 13A). Notably, colorectal tumors with 
mutant TP53 showed  more pronounced correlation between miR-34a promoter 
methylation and down-regulation of miR-34a expression compared to colorectal 
tumors with wt TP53 (Figure 13B-C). In addition, we found that colorectal tumors with 
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mutant TP53 display higher levels of CpG methylation within the MiR-34a promoter, 
which was associated with decreased miR-34a expression when compared to 
colorectal tumors with wt TP53 (Figure 13D-E). Furthermore, miR-34a expression 
was the lowest in tumors with both, elevated MIR34A methylation and TP53 mutation 
(Figure 13F).  
 
 
Figure 13. Preferential miR-34a silencing in CRCs with mutant TP53. 
CRC samples from 208 patients of the TCGA CRC dataset (COAD+READ) that have a 
confirmed TP53 wild type (wt; n=81) or TP53 mutant (n=127) status were analyzed. (A) 
Correlation of miR-34a expression and methylation in 208 CRCs. Correlation of miR-34a 
expression and methylation in (B) TP53 wt and (C) TP53 mutant CRCs. (A-C) Correlation 
coefficients (r) and p-values were calculated by Spearman correlation. (D) Methylation of 
MIR34A in TP53 wt vs. TP53 mut. CRCs: (E) Expression of miR-34a in TP53 wt (n=81) vs. 
mut. (n=127) CRCs. (D+E) Significance was calculated by Student´s t-test (F) miR-34a 
expression in, 208 CRCs. Significance was calculated by one-way ANOVA with Dunnett 
multiple-comparisons post-test. P values are provided as *P < 0.05 and ***P <0 .001. Figures 
(A-F) were generated by Dr. Matjaz Rokavec. 
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These results prompted us to experimentally determine whether the Mir34a 
and Tp53 genes cooperatively suppress colorectal tumorigenesis and to investigate 
the underlying molecular mechanisms in a mouse model of sporadic CRC. In 
addition, this would allow us to test potential therapeutic strategies for the treatment 
of Mir34a/Tp53-deficient colorectal carcinomas. For this purpose we generated mice 
with Mir34a and Tp53 alleles flanked by loxP sites, which permit intestinal epithelial 
cell (IEC) specific deletion by Cre recombinase expressed from a Villin promoter 
(Figure 14A). We did not analyze the effect of Mir34b/c-deficiency in this study, since 
Mir34b/c is expressed at least hundred times lower than Mir34a in IECs (data not 
shown). Mice with IEC-specific deletion of Mir34a (Mir34aΔIEC) or Tp53 (Tp53ΔIEC), as 
well as their combined deletion (Mir34aΔIECTp53ΔIEC) did not display any overt 
phenotype or any signs of spontaneous tumorigenesis in the colon (data not shown). 
Tp53 expression was decreased in the IECs of Mir34aΔIEC mice compared to 
Mir34aFl/Fl/Tp53Fl/Fl mice and it was absent in Tp53ΔIEC and Mir34aΔIECTp53ΔIEC mice 
(Figure 14B). Mir34Fl/Fl/Tp53Fl/Fl mice were used as controls. To induce sporadic 
CRC, 6-10 week old mice were treated weekly with the carcinogen Azoxymethane 
(AOM), which is known to induce activating β-catenin mutations (Takahashi et al., 
2000), for a period of 6 weeks as described previously (Schwitalla et al., 2013) 
(Figure 14C). 
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Figure 14. Strategy for IEC-specific deletion of Mir34a/Tp53 and treatment scheme 
employed for generating sporadic CRCs in mice.  
(A) Schematic illustration of the genetic strategy employed for intestinal epithelial cell (IEC) 
specific deletion of Mir34a and Tp53. LoxP sites are indicated by triangles. Open rectangles 
represent exons. Arrows indicate the transcriptional start sites. (B) 8 hours after i.p. AOM 
injection (10mg/kg) intestinal tissue was isolated from the indicated mice and 2 µM FFPE 
sections were prepared. Detection of Tp53 in normal colon epithelium by IHC. Number of 
positive cells was determined in ≥50 crypts per mouse (n=2 mice for each genotype). Mean 
values ±SEM are provided. Mean values ±SEM are provided, *P < 0.05, ***P < 0.001 by 
Student´s t-test. (C) Scheme for inducing sporadic CRCs by weekly i.p. injection of mice with 
AOM (10 mg/kg). 
 
16 weeks after the initial treatment all Mir34aΔIECTp53ΔIEC mice had already 
succumbed to advanced CRC formation with ascites, whereas only ~60% of Tp53ΔIEC 
mice succumbed to CRCs by 24 weeks. At this time-point none of the 
Mir34aFl/Fl/Tp53Fl/Fl and Mir34aΔIEC mice displayed any complications due to CRC 
formation (Figure 15A).   
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Deletion of Mir34a or Tp53 increased the number and size of colonic tumors 
(Figure 15B, C, and D). Combined deletion of Mir34a and Tp53 further increased 
these effects. Moreover, the size distribution of tumors was skewed towards larger 
tumors in Mir34aΔIECTp53ΔIEC mice (Figure 15E). None of the analyzed mice showed 
tumors in other organs. Taken together, these results show that Mir34a and Tp53 
cooperatively suppress colorectal tumorigenesis. 
 
 
 
Figure 15. Mir34a and Tp53 cooperatively suppress CRC initiation, growth, invasion 
and metastasis. 
(A) Kaplan-Meier survival analysis of mice with the indicated genotypes. Significance was 
calculated by a log-rank test. (B) Representative morphology of intestinal tumors 16 weeks 
after initial AOM injection. Scale bars represent 1 mm. (C) Tumor incidence and (D) mean 
size in mice with the indicated genotypes (n=7 per genotype) (E) Size distribution of tumors. 
C-E: 7 mice of each genotype were sacrificed at week 16. Mean values ±SEM are provided, 
*P < 0.05, ***P <0 .001 by Student´s t-test. “Control” corresponds to Mir34aFl/Fl/Tp53Fl/Fl mice. 
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Whereas Mir34aFl/Fl/Tp53Fl/Fl and Mir34aΔIEC mice did not display invasive 
tumors, colonic tumors invaded into the submucosa in Tp53ΔIEC and 
Mir34aΔIECTp53ΔIEC mice (Figure 16A). Invasion was more pronounced in the 
Mir34aΔIECTp53ΔIEC mice than in Tp53ΔIEC mice (Figure 16B). In addition, only CRCs 
in Mir34aΔIECTp53ΔIEC mice showed peritoneal invasion (Figure 16C). Therefore, 
advanced tumors with obstructive growth and aggressive invasion into the peritoneal 
cavity in Mir34aΔIECTp53ΔIEC mice might explain their shortened survival when 
compared to mice with other genotypes. Notably, only Mir34aΔIECTp53ΔIEC mice 
showed lymph node metastasis by week 16 (Figure 16A-C). In a previous report, 
lymph node metastases in Tp53ΔIEC mice could only be detected by week 24, 
whereas after 16 and 20 weeks primary tumor were only associated with local 
invasion (Schwitalla et al., 2013). Therefore, the combined inactivation of Mir34a and 
Tp53 enhances invasion and accelerates lymph-node metastasis of colonic tumors.  
 
Figure 16. Combined Mir34a and Tp53 deletion enhances invasion and metastasis. 
(A) (left) H&E stained sections. Detection of tumor cell invasion. White dashed line: lamina 
muscularis mucosae as the border of primary tumor and invasive area green arrows: 
invasion to submucosa; yellow arrows invasion to muscularis externa. Scale bars: 50 µm and 
100 μm (insert). (right) Quantification of tumor invasion (n=7 mice per genotype). (B) 
Quantification of invasive tumors (91 tumors from p53ΔIEC mice and 249 tumors from 
Mir34aΔIECp53ΔIEC mice were evaluated, n=7 mice per genotype). (C) (left) Detection of 
metastasized cells in lymph nodes of Mir34aΔIECTp53ΔIEC mice. (right) Frequency of lymph-
node metastasis. Mean values ±SEM are provided, *P <0.05, **P <0.01, ***P <0.001 by 
Student´s t-test. (A) Significance was calculated by Fisher´s exact test, p values are provided 
as **P < 0.01, ***P <0 .001. “Control” corresponds to Mir34aFl/Fl/Tp53Fl/Fl mice. 
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4.4  Enhanced proliferation in the presence of DNA damage in Mir34a/Tp53-
deficient IECs 
The genotoxic agent AOM induces DNA damage in the colonic epithelium of 
rodents and Tp53-dependent apoptosis in IECs (Toft et al., 1999). Previously, the 
increased tumor formation observed in AOM-treated Tp53ΔIEC mice was linked to a 
decrease in apoptosis (Schwitalla et al., 2013). Here, the combined loss of Tp53 and 
Mir34a further reduced the frequency of IECs undergoing apoptosis 8 hours after 
treatment with AOM (Figure 17A). Moreover, the frequency of epithelial cells positive 
for the DNA damage marker phosphorylated γ-H2AX and cellular proliferation was 
increased in colonic crypts of Mir34aΔIECp53ΔIEC mice when compared to crypts 
lacking only Tp53 or Mir34a (Figure 17B-C). Taken together, these results suggest 
that the combined deficiency of Mir34a and Tp53 allows IECs to escape DNA 
damage-induced apoptosis and cell cycle arrest. The continuing proliferation of 
Mir34a/Tp53-deficient cells that have acquired DNA damage may not allow adequate 
repair and ultimately lead to an increased number of mutations in oncogenes and 
tumor-suppressor genes which may cause the increased rate of colonic tumor 
initiation of Mir34aΔIECTp53ΔIEC mice. 
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Figure 17. Enhanced proliferation in the presence of DNA damage in Mir34a/Tp53-
deficient IECs.  
8 hours after i.p. AOM injection (10mg/kg) intestinal tissue was isolated from the indicated 
mice and 2 µM FFPE sections were prepared.  
(A) Detection of apoptosis in normal intestinal epithelium by cleaved caspase 3 IHC. Number 
of positive cells was determined in ≥50 crypts per mouse (n=2 mice for each genotype). (B) 
Detection of phosphorylated γH2AX (p-γH2AX) as in A. (C) Detection of Ki67-positive cells 
as in A. (A-C) Mean values ±SEM are provided, *P < 0.05, **P <0.01, ***P < 0.001 by 
Student´s t-test. Scale bars: 50 µm. “Control” corresponds to Mir34aFl/Fl/Tp53Fl/Fl mice. 
 
4.5 Enhanced survival, proliferation and stromal infiltration in Mir34a/Tp53-
deficient CRCs 
Since the combined deletion of Mir34a and Tp53 in IECs enhanced the size of 
colonic tumors, we hypothesized that this may be due to increased tumor cell 
proliferation and decreased apoptosis. Indeed, colonic tumors from 
Mir34aΔIECTp53ΔIEC mice displayed the highest proliferation and lowest apoptosis 
rates when compared to tumors from mice with the other genotypes (Figure 18A, B). 
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Since enhanced infiltration of tumors with bacteria and macrophages has previously 
been implicated in CRC progression (Schwitalla et al., 2013), we determined whether 
these parameters are affected by combined deletion of Tp53 and Mir34a. Indeed, 
infiltration of F4/80-positive macrophages was highest at the invasion front of tumors 
from Mir34aΔIECTp53ΔIEC mice and showed an intermediate increase in Tp53ΔIEC 
tumors when compared to tumors from Mir34aFl/Fl/Tp53Fl/Fl and Mir34aΔIEC mice 
(Figure 18C). Furthermore, infiltration by CD3+T-cells was increased in tumors of 
Mir34aΔIEC, Tp53ΔIEC and Mir34aΔIECTp53ΔIEC mice when compared to 
Mir34aFl/Fl/Tp53Fl/Fl mice (Figure 18D). 
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Figure 18. Enhanced survival, proliferation and infiltration in Mir34a/Tp53–deficient 
tumors. 
(A) Proliferation of tumor cells was determined by BrdU incorporation. (left panels) 
Representative IHC detection of BrdU incorporation. (right) Quantification of proliferation 
(n=5 mice for each genotype). (B) Determination of apoptosis of tumor cells by IHC for 
cleaved caspase 3. (left) Representative IHC detection of cleaved caspase 3. (right) 
Quantification of apoptosis (n≥5 mice for each genotype). (C) (left) Representative IHC 
detection of F4/80+macrophages at the invasion front of tumors. (right) Quantification of 
F4/80-positive cells in CRCs (n≥3 mice per genotype). (D) (left) Representative IHC staining 
of CD3+T-cells in tumors. (right) Quantification of CD3+T-cells in tumors (n≥3 mice per 
genotype). (A-D) Mean values ±SEM are provided. n.s. not significant, *P <0 .05, **P < 0.01, 
***P <0.001 by Student´s t-test. Scale bars: 50 µm. “Control” corresponds to 
Mir34aFl/Fl/Tp53Fl/Fl mice. 
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Notably, tumors from Mir34aΔIECTp53ΔIEC mice showed increased bacterial 
infiltration when compared to tumors from Mir34aFl/Fl/Tp53Fl/Fl, as well as Tp53- and 
Mir34a-deficient mice, which displayed an intermediate degree of infiltration (Figure 
19A). Therefore, combined Mir34a and Tp53 inactivation presumably enhances a 
barrier-defect. In line with the most pronounced bacterial infiltration, the mRNA levels 
of tight junction components Claudin15, Claudin6 and Mucin5 were down-regulated 
in Mir34aΔIECTp53ΔIEC CRCs to a larger extent than in the single knock-out tumors 
(Figure 19B-D). On the other hand, expression of Mucin1, whose elevated 
expression has been associated with a higher tumor stage in CRC (Lugli et al., 
2007), was up-regulated in Mir34aΔIECTp53ΔIEC CRCs (Figure 19E).  
 
 
 
Figure 19. Effect of Mir34a/Tp53 inactivation in tumors on bacterial infiltration and 
expression of tight junction components.  
(A) (left) Detection of microbes using FISH with a FITC-labeled universal eubacteria probe 
EUB 338. (right) Quantification of EUB338 scoring (n≥3 mice per genotype). (B-E) qPCR 
analysis of Cldn15, Muc5, Cldn6 and Muc1 mRNAs in tumors of indicated genotypes (n≥5 
tumors per genotype). Mean values ±SEM are provided, n.s. not significant, *P < 0.05, ***P 
<0 .001 by Student´s t-test. “Control” corresponds to Mir34aFl/Fl/Tp53Fl/Fl mice. 
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Interestingly, down-regulation of Claudin15, Claudin6 and Mucin5 mRNA 
expression was also observed in normal IECs of Mir34aΔIEC, Tp53ΔIEC, 
Mir34aΔIECTp53ΔIEC mice not treated with AOM (Figure 20A-C). However, colonic 
epithelia of these mice did not display bacterial infiltration (Figure 20D). Therefore, 
the down-regulation of these genes is not sufficient to cause a barrier defect in 
normal colon epithelium. Further changes that occur during tumor progression (e.g. 
EMT) may cooperate with the down-regulation of the barrier components and thereby 
contribute to the bacterial infiltration. In addition, the enhanced bacterial infiltration in 
Mir34aΔIECTp53ΔIEC mice might alter the recruitment of myeloid cells. The resulting 
inflammatory tumor microenvironment may further promote tumor progression. 
 
 
Figure 20. Effect of Mir34a/Tp53 inactivation in normal colon epithelium on bacterial 
infiltration and expression of tight junction components. 
(A-C) qPCR analysis of Cldn15, Muc5, Cldn6 and Muc1 mRNAs in normal colon epithelium 
of indicated genotypes (n≥5 tumors per genotype). (D) (left) Detection of microbes using 
FISH with a FITC-labeled universal eubacteria probe EUB 338. (right) Quantification of 
EUB338 scoring (n=2 mice per genotype). Mean values ±SEM are provided, n.s. not 
significant, *P < 0.05 by Student´s t-test. “Control” corresponds to Mir34aFl/Fl/Tp53Fl/Fl mice. 
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4.6 RNA expression profiles of Mir34aΔIECTp53ΔIEC-deficient tumors 
In order to identify mediators of the enhanced CRC progression resulting from 
combined inactivation of Mir34a and Tp53, we compared the mRNA expression 
profiles of AOM-induced colonic tumors derived from Mir34aFl/Fl/Tp53Fl/Fl, Mir34aΔIEC, 
Tp53ΔIEC and Mir34aΔIECTp53ΔIEC mice. For each genotype RNAs obtained from 9 
tumors derived from three mice were subjected to RNA-Seq. Since we had observed 
an increase in the degree of tumor aggressiveness from Mir34aFl/Fl/Tp53Fl/Fl over 
Mir34aΔIEC and Tp53ΔIEC to Mir34aΔIECTp53ΔIEC mice, we aimed to identify mRNAs 
that were increasingly expressed in this order and would therefore be potentially 
associated with increased aggressiveness by performing a t-test for trend. Thereby, 
1284 up- and 1372 down-regulated mRNAs matching to this pattern were identified 
(P <0.05; Figure 21A). In addition, principle component analysis of mRNA expression 
profiles showed a good concordance between the three samples sequenced for each 
genotype (Figure 21B). Gene Set Enrichment Analyses (GSEA) revealed that up-
regulated mRNAs were enriched in Hallmark MSigDB signatures associated with 
tumor initiation and progression, such as c-Myc targets, hypoxia, epithelial 
mesenchymal transition (EMT), inflammatory response and Kras signaling (Figure 
21C). As expected, down-regulated mRNAs displayed the most significant 
enrichment within the Tp53 pathway hallmark MSigDB signature (Figure 21D). 
Comparison of the signature of RNAs significantly up-regulated in Mir34aΔIECTp53ΔIEC 
tumors (t-test for trend; P <0.05) with the consensus molecular subtypes (CMS) of 
human CRC (Dienstmann et al., 2017; Guinney et al., 2015) represented in the 
TCGA database showed highest concordance with the CMS4 subtype, which 
displays mesenchymal characteristics associated with a high metastatic potential and 
the poorest prognosis of all CRC subtypes (Figure 21E). In accordance with an 
enrichment of c-Myc targets among up-regulated mRNAs, c-Myc mRNA expression 
was most significantly up-regulated in tumors from Mir34aΔIECTp53ΔIEC mice and to a 
lower degree in Tp53-deficient tumors (Figure 21F). 
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Figure 21. RNA expression profiles of Mir34aΔIEC and/or Tp53ΔIEC–deficient tumors. 
(A) Heat-map of mRNA expression in colon tumors with the indicated genotypes. RNAs that 
displayed a significant (t-test for trend; *P <0.05) up- or down-regulation from 
Mir34aFl/Fl/Tp53Fl/Fl to Mir34aΔIECTp53ΔIEC mice are shown. (B) Principal component analysis 
of RNA expression in tumors from mice with the indicated genotypes. (C-D) GSEA analyzes 
of the RNAs that displayed a significant (t-test for trend; *P < 0.05) up- (C) or down-
regulation (D) in tumors from Mir34aFl/Fl/Tp53Fl/Fl to Mir34aΔIECTp53ΔIEC mice. The ten MSigDB 
Hallmark gene sets with the most significant association are shown. (E) Association of 
signature of mRNAs up-regulated in colon tumors of Mir34aΔIECTp53ΔIEC mice with the 
consensus molecular subtypes (CMS) of CRC in TCGA CRC datasets. N is number patients 
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in each CMS group. Expression of the mRNA signature was calculated as average of z-score 
normalized expression of all mRNAs from the signature in the TCGA CRC dataset. (F) qPCR 
analysis of c-Myc mRNA in tumors of mice with the indicated genotypes (n≥7 tumors per 
genotype). Mean values ±SEM are provided, n.s. is not-significant, **P < 0.01, ***P < 0.001 
by Student´s t-test. “Control” corresponds to Mir34aFl/Fl/Tp53Fl/Fl mice. Figures (A-E) were 
generated by Dr. Matjaz Rokavec. 
 
4.7 IL6/Stat3 pathway activation in CRCs of Mir34aΔIECTp53ΔIEC mice 
The comparison of expression profiles of Mir34aFl/Fl/Tp53Fl/Fl and 
Mir34aΔIECTp53ΔIEC CRCs showed a significant enrichment of the MSigDB 
IL6/IL6R/Stat3 pathway signature in Mir34aΔIECTp53ΔIEC tumors (Figure 22A). Since 
we have previously shown that Mir34a suppresses colitis-associated colon-cancer 
(CAC) progression via directly targeting the IL6 receptor (IL6R) and thereby inhibiting 
Stat3 activity (Rokavec et al., 2014b), we further analyzed the effects of Mir34a 
and/or Tp53 deletion on the IL6R/Stat3 pathway in sporadic CRCs. By qPCR 
analysis we confirmed that mRNA levels of IL6, IL11 and IL6Rα were significantly 
increased in Mir34aΔIECTp53ΔIEC mice tumors when compared to tumors from 
Mir34aFl/Fl/Tp53Fl/Fl, Mir34aΔIEC and Tp53ΔIEC mice (Figure 22B). Moreover, the levels 
of phosphorylated and therefore activated Stat3 protein were increased in Tp53-
deficient tumors and further increased in Mir34a/Tp53-deficient tumors (Figure 22C). 
In addition, key mediators of EMT, such as Snail and Zeb1, as well as EMT effectors, 
as Vimentin, were up-regulated in Mir34a/Tp53-deficient tumors (Figure 22D). SNAIL 
expression was presumably caused by STAT3 activation, since SNAIL represents a 
known target of STAT3 (Saitoh et al., 2016). Since SNAIL is also a target of miR-34a 
(Siemens et al., 2011), the loss of Mir34a may also directly contribute to the elevated 
levels of SNAIL. Taken together, the combined inactivation of Mir34a and Tp53 
synergistically activates the IL6R/Stat3 pathway to a larger degree than Tp53 or 
Mir34a inactivation alone. 
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Figure 22. IL6/Stat3 pathway activation in CRCs of Mir34aΔIECTp53ΔIEC mice. 
(A) GSEA analyzes of the MSigDB Hallmark IL6/Stat3 mRNA signature in the colon tumors 
from Mir34aΔIECTp53ΔIEC versus Mir34aFl/Fl/Tp53Fl/Fl mice. Figure is generated by Dr. Matjaz 
Rokavec. (B) qPCR analysis of indicated mRNAs in colonic tumors (n≥5 mice per genotype). 
(C) (left) IHC detection of p-Stat3 in tumors of indicated genotypes. Scale bars represent 20 
µm. (right) Quantification of p-Stat3-positive cells in CRCs. (D) PCR analysis of indicated 
mRNAs in colonic tumors (n≥5 mice per genotype). (B-D) Mean values ±SEM are provided, 
n.s. not-significant, *P <0.05, **P < 0.01 by Student´s t-test. “Control” corresponds to 
Mir34aFl/Fl/Tp53Fl/Fl mice. 
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4.8 IL6/Stat3 pathway blockade reduces tumor progression in 
Mir34aΔIECTp53ΔIEC mice 
To determine the relevance of IL6R/Stat3 pathway up-regulation for the 
enhanced tumor progression in Mir34aΔIECTp53ΔIEC mice we employed the IL6R-
neutralizing antibody MR16-1, which competitively inhibits binding of IL6 to both 
soluble and membrane-associated IL6R (Becker et al., 2004b). Three weeks after 
6xAOM treatment mice received either weekly i.p. injections of 1 mg of MR16-1 
antibody or, as a control, 1 mg of isotype-matched IgG1 for a period of 7 weeks 
(Figure 23A). Detection of reduced Stat3 phosphorylation in colonic tumors of MR16-
1 treated animals confirmed the efficacy of IL6R inhibition (Figure 23B). Treatment 
with MR16-1 did not significantly affect the number of colonic tumors in 
Mir34aΔIECTp53ΔIEC mice (Figure 23C). However, MR16-1 treatment significantly 
reduced the average tumor size and cell proliferation in Mir34aΔIECTp53ΔIEC mice 
(Figure 23D, E). Importantly, treatment with MR16-1 decreased the size of invasive 
areas and the incidence of invasive tumors (Figure 23F). In addition, MR16-1 
prevented the formation of lymph node metastases (Figure 23G). In summary, 
blockade of the IL6/IL6R/Stat3 pathway inhibited tumor cell proliferation, invasion and 
lymph-node metastasis of colonic tumors in Mir34aΔIECp53ΔIEC mice. Therefore, 
activation of the IL6R/Stat3 pathway is required for tumor progression in CRC with 
combined inactivation of Mir34a and Tp53. 
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Figure 23. Blocking IL6/Stat3 pathway reduces CRC progression in Mir34a/Tp53-
deficient mice. 
 (A) Scheme of therapeutic intervention with the IL6Rα-blocking antibody MR16-1 in the 
sporadic CRC mouse model. Mice received weekly i.p. injections of MR16-1 (1 mg) or, an 
IgG1 isotope control antibody (1 mg) 9 to 16 weeks after the initial AOM treatment. (B) (left)  
IHC detection of p-Stat3 in colonic tumors of Mir34aΔIECTp53ΔIEC mice with the indicated 
treatments. Scale bars represent 20 µm. (right) Quantification of p-Stat3-positive cells in 
tumors. (C-D) Tumor incidence and (D) mean tumor size (138 tumors from 
Mir34aΔIECTp53ΔIEC mice treated with IgG and 103 tumors from Mir34aΔIECTp53ΔIEC mice 
treated with MR16-1 were evaluated, n=6 mice for each group). (E) (left) IHC detection of 
BrdU incorporation in tumors of Mir34aΔIECTp53ΔIEC mice treated as indicated. Scale bars 
represent 20 µm. (right) Percentage of proliferation in tumors. (F) (left) Representative 
micrographs of tumor invasion in Mir34aΔIECTp53ΔIEC  mice treated as indicated. White dashed 
line: lamina muscularis mucosae as the border between primary tumor and invasive area; 
green arrows: invasion to submucosa; yellow arrows invasion to muscularis externa. Scale 
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bars represent 500 μm. Quantification of mean invasive area (middle) and (right) invasion in 
tumors (11 tumors Mir34aΔIECTp53ΔIEC mice treated with IgG and 9 tumors from 
Mir34aΔIECTp53ΔIEC mice treated with MR16-1 were evaluated, n=6 mice for each treatment 
group). (G) (left) Detection of metastatic tumor cells in the lymph nodes of mice of indicated 
treatments. (right) Quantification of lymph node metastases in Mir34aΔIECTp53ΔIEC mice 
treated as indicated. Scale bars represent 20 μm. (B-F) Mean values ±SEM are provided, *P 
<0 .05, ***P < 0.001 by Student´s t-test, n.s. not-significant. 
 
4.9 Association of elevated PAI-1 with CRC metastasis and poor survival 
Among the genes up-regulated in colonic tumors after combined Mir34a/Tp53-
deletion (Table 9.1) Pai-1 (Serpine1) showed the most pronounced correlation with 
the Hallmark gene sets of EMT and inflammatory response (Tables 9.6 and 9.7) and 
was also highly associated with the hypoxia related gene set (Table 9.5). Pai-1 
mRNA showed one of the most pronounced up-regulations in IECs and colonic 
tumors of Mir34aΔIECTp53ΔIEC mice (Figure 24A) as determined by mRNA-Seq and 
qPCR analysis (Figure 21A, 24A). Also Pai-1 protein levels were increasingly up-
regulated in tumors from Mir34a-, Tp53- and Mir34/Tp53-deficient mice (Figure 24B). 
Notably, the Pai-1 3’-UTR contains a conserved Mir34a seed-matching sequence, 
suggesting that it represents a direct Mir34a target (Figure 24C). Indeed, transfection 
of murine CT26 CRC cells with pre-miR-34a oligonucleotides resulted in repression 
of Pai-1 mRNA expression (Figure 24D). In addition, a reporter plasmid harboring the 
Pai-1 3’-UTR was repressed by ectopic pre-miR-34a, whereas a reporter with a 
mutant seed-match sequence was refractory to pre-miR-34a (Figure 24C, E). Taken 
together, these results show that Pai-1 is a direct Mir34a target.  
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Figure 24. Pai-1 is a direct miR-34a target.  
(A) qPCR analysis of Pai-1 mRNA expression (left) in intestinal epithelial cells (IECs) and 
(right) in CRCs (n≥5 tumors per genotype). Mean values ±SEM are provided, *P < 0.05, **P 
< 0.01, ***P < 0.001 by Student´s t-test. (B) Western blot analysis of Pai-1 protein from CRC 
lysates (n=2 tumors per genotype). (C) Schematic representation of the Pai-1 (Serpine1) 3'-
UTR indicating the Mir34a seed-matching sequence and its phylogenetic conservation as 
determined by miRwalk target prediction algorithm. Above the mutations in the seed-
matching sequence used in Figure 24E are indicated in red. (D) qPCR analysis of Pai-1 
mRNA expression in CT26 cells transfected with pre-miR-34a (n=3 per group). cDNA was 
provided by Dr. Nassim Bouznad. (E) Dual-reporter luciferase assay was performed in 
H1299 cells transfected with the indicated oligonucleotides and reporter constructs (n=3). 
“Control” corresponds to Mir34aFl/Fl/Tp53Fl/Fl mice. 
 
To assess the association between PAI-1 expression and MIR34A 
methylation/TP53 mutation in human tumors, we employed primary colon cancer 
samples of 61 patients in which MIR34A methylation and TP53 mutational status had 
been previously determined (Siemens et al., 2013). In these samples MIR34A 
methylation and expression showed a significant, negative correlation (Siemens et 
al., 2013). Expression of PAI-1 was increased from MIR34A MCpG low/TP53 wt over 
MIR34A MCpG high/TP53 wt and MIR34A MCpG low/TP53 mutant to MIR34A MCpG 
high/TP53 mutant tumors (Figure 25A). In addition, PAI-1 expression was highest in 
the invasion front of MIR34A MCpG high/TP53 mutant tumors. Therefore, the up-
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regulation of PAI-1 is conserved between murine and human colorectal tumors that 
display combined TP53 and MIR34A inactivation.  
 In order to determine whether elevated PAI-1 expression in colonic tumors is 
associated with clinical parameters in patients we analyzed the TCGA COAD (colon 
adenocarcinomas) and READ (rectal adenocarcinomas) database: PAI-1 expression 
was significantly elevated in primary tumors from 48 CRC patients when compared to 
matched normal tissues (Figure 25B).  Furthermore, PAI1 expression was 
significantly elevated in primary colorectal tumors from patients with local (nodal 
status pN2) or distant metastasis when compared to colorectal tumors without 
metastasis (Figure 26A, Figure 25C). PAI-1 mRNA expression was highest in CRC 
tumors belonging to the mesenchymal subtype CMS4 within the TCGA CRC dataset 
(Figure 25D). In line with these results, PAI-1 expression was also elevated in liver 
metastasis compared to matched primary, colonic tumors of 17 patients (Figure 25E). 
Furthermore, increased PAI-1 expression in the primary colorectal tumors was 
associated with poor overall and relapse-free survival of 628 patients with colorectal 
adenocarcinomas represented in TCGA database and also in 4 additional, 
independent cohorts of CRC patients (Figure 25F, Figure 26B-F).  
Taken together, these results show that elevated expression of PAI-1 is associated 
with a mesenchymal-like cancer cell state, metastasis, and poor survival in human 
CRC. Therefore, PAI-1 may represent a clinically relevant prognostic marker for 
CRC. 
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Figure 25. Altered PAI-1 expression in human primary colon carcinomas and 
association of PAI-1 expression with different entities from TCGA COAD+READ CRC 
dataset. 
(A) Determination of PAI-1 expression in human primary colon carcinomas by IHC in 
indicated groups of patients. Number of patients analyzed per each group is: Group I n=15, 
group II n=12, group III n=22 and group IV n=12. (Upper-panel) (left) Representative 
micrographs and (right) quantification of PAI-1 expression in tumors, (bottom-panel) similar 
analysis of the invasive front of the respective CRCs. Scale bars represent 100 μm. Mean 
values ±SEM are provided, *P<0.05, **P<0.01 by Student´s t-test, n.s. not significant. (B) 
Expression of PAI-1 mRNA in paired samples from normal colonic tissue and CRC tumors 
from the TCGA CRC dataset (n=48). Significance calculated by paired-t-test. (C) Association 
of PAI-1 mRNA expression with distant metastasis (H) in the TCGA CRC dataset (n=628) 
comprising colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ). (D) 
Association of PAI-1 mRNA expression with the consensus molecular subtypes (CMS) of 
colorectal cancer in TCGA COAD+READ CRC dataset (n=628). (E) PAI-1 expression in 17 
pairs of primary colon cancer tumors and matched liver metastases (data from GSE14297). 
Significance calculated by paired-t-test. (F) Association of PAI-1 mRNA expression with 
overall survival in the TCGA CRC dataset (n=628). (A) Human primary colon carcinoma 
samples were provided by Prof. Thomas Kirchner and Prof. David Horst. Samples were 
stained by the diagnostics laboratory, Pathology Institute, LMU, Munich. Meryem Gülfem 
Öner-Ziegler evaluated the staining, made the pictures, and generated the figure with Prof. 
David Horst´s approval. (C, D) Values on y-axis are shown in log10 scale. Figures (B-F) were 
generated by Dr. Matjaz Rokavec. 
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Figure 26. Elevated PAI-1 mRNA expression is associated with local metastasis and 
poor survival in additional patient cohorts.  
(A) Association of PAI-1 mRNA expression with nodal status/local metastasis in the TCGA 
CRC dataset (N=628) comprising colon adenocarcinoma (COAD) and rectal 
adenocarcinoma (READ). Values on y-axis are shown in log10 scale. (B) Association of PAI-
1 mRNA expression with relapse free survival in the TCGA CRC dataset (N = 628). (C-F) 
Association of PAI-1 mRNA expression with relapse free survival in four different CRC 
cohorts. Kaplan-Meier survival analysis was used in combination with a log-rank test. 
Expression and clinical data of GSE39582, GSE37892, GSE17536, and GSE14333 datasets 
was down- loaded from NCBI GEO (www.ncbi.nlm.nih.gov/geo). Figures (A-F) were 
generated by Dr. Matjaz Rokavec. 
 
4.10 Targeting of Pai-1 inhibits initiation and progression of Mir34a/Tp53-
deficient CRCs 
To determine the relevance of Pai-1 up-regulation in colonic tumors of 
Mir34aΔIECTp53ΔIEC mice and its therapeutic value we employed Tiplaxtinin, a small 
drug inhibitor of Pai-1, which was described before (Elokdah, 2004). After treatment 
with AOM for 6 weeks Mir34aΔIECTp53ΔIEC mice were fed with Tiplaxtinin 
supplemented chow or with normal chow (as controls) starting from week 9 until 
week 16 (Figure 27A). Treatment with Tiplaxtinin reduced the incidence and size of 
colonic tumors in Mir34aΔIECTp53ΔIEC mice (Figure 27B-D), whereas it did not affect 
A B C
D E F
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the rate of apoptosis within these (Figure 27E). In addition, Tiplaxtinin treatment led 
to decreased cellular proliferation (Figure 27F), which may explain the reduced size 
of colonic tumors detected in treated Mir34aΔIECTp53ΔIEC mice. Moreover, Tiplaxtinin 
treatment decreased the invasive area of colonic tumors and prevented the formation 
of lymph node metastases in Mir34aΔIECTp53ΔIEC mice (Figure 27G-I).  
In summary, inhibition of Pai-1 suppressed the enhanced tumor growth, 
invasion and lymph node metastasis of colonic tumors in Mir34aΔIECTp53ΔIEC mice. 
These results indicate that elevated expression of Pai-1 critically contributes to the 
CRC promoting effects of Mir34a/Tp53-deficiency.  
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Figure 27. Targeting of Pai-1 inhibits initiation, invasion and lymph node metastasis of 
Mir34a/p53-deficient CRCs.  
(A) Therapeutic application of Tiplaxtinin within the 6xAOM protocol. Starting from week 9 
mice were fed with Tiplaxtinin supplemented chow (1g Tiplaxtinin/kg chow) or normal chow 
until week 16 (Control group). (B) Representative micrographs of colon morphology from 
Mir34aΔIECTp53ΔIEC fed with normal or Tiplaxtinin supplemented chow. Scale bars represent 1 
mm. (C) Tumor incidence and (D) mean tumor size (n=6 mice for each treatment group; 156 
tumors from Mir34aΔIECTp53ΔIEC  mice treated with normal chow and 68 tumors from 
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Mir34aΔIECTp53ΔIEC mice treated with Tiplaxtinin supplemented chow were evaluated). (E) 
Quantification of apoptosis in tumor cells as determined by cleaved caspase 3 IHC. (F) (left) 
IHC detection of BrdU incorporation from colonic tumors. Scale bars represent 20 µm. (right) 
Quantification of proliferation. (G) (left) Representative micrographs of tumor invasion in 
Mir34aΔIECTp53ΔIEC  mice treated as indicated. White dashed line: lamina muscularis 
mucosae as the border of primary tumor and invasive area green arrows: invasion to 
submucosa; yellow arrows invasion to muscularis externa. Scale bars represent 100 μm. (H) 
Quantification of tumor invasion. Significance is calculated by Fisher´s exact test, P value is 
*, P <0.05. (I) (left) Detection of metastatic cancer cells in the lymph node of mice with 
indicated treatments. (right) Evaluation of lymph node metastases in Mir34aΔIECTp53ΔIEC mice 
treated as indicated. Scale bars represent 20 μm. (C-H) Mean values ±SEM are provided, *P 
< 0.05 by Student´s t-test. 
 
Next we determined whether inhibition of the Pai-1 has any effects on the 
IL6/Stat3 pathway and vice versa. Upon treatment with MR16-1 Pai-1 levels did not 
change in colonic tumors of Mir34aΔIECTp53ΔIEC mice (Figure 28A). Furthermore, 
Tiplaxtinin treatment did not affect IL6R mRNA expression or Stat3 phosphorylation 
in colonic tumors of Mir34aΔIECTp53ΔIEC mice (Figure 28B-C). Therefore, the two 
pathways are presumably not connected in colon tumors. 
Figure 28. Treatment with MR16-1 does not affect the Pai-1 pathway and Tiplaxtinin 
does not affect the IL-6/Stat3 pathway in Mir34aΔIECTp53ΔIEC mice.  
(A) Western-blot analysis of Pai-1 from colonic tumors of Mir34aΔIECTp53ΔIEC mice treated 
with MR16-1 or IgG (control) (n=3 tumors per genotype). (B) qPCR analysis of IL6Rα mRNA 
from tumors of Mir34aΔIECTp53ΔIEC mice treated with Tiplaxtinin supplemented chow or 
normal chow (control). (C) (left) IHC detection of p-Stat3 in tumors of Mir34aΔIECTp53ΔIEC mice 
with indicated treatments. Scale bars represent 20 µm. (right) Quantification of p-Stat3-
positive cells in tumors. Mean values ±SEM are provided, n.s. not-significant by Student´s t-
test.  
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5 Discussion 
 
In the first part of this study, the role of Mir34a in mouse models of a CAC was 
investigated. As it was demonstrated in vitro , miR-34a functions in the context of a 
feedback-loop consisting of IL6R, STAT3 and miR-34a (Rokavec et al., 2014b). 
Repression of miR-34a induces IL6R/STAT3 signaling and SNAIL expression which 
contributes to EMT. To determine the relevance of these results in vivo, Mir34aF/F and 
Mir34a-/- mice were generated and the AOM/DSS model was used to induce colitis-
associated colorectal cancer. In line with the in vitro evidence, the first part of the 
study demonstrated the relevance of the IL6-triggered IL6Ra/Stat3/Mir34a feedback 
loop that controls EMT for the formation of invasive colon tumors in Mir34a-deficient 
mice. Therefore, this study provided the first in vivo proof for a tumor suppressive 
function of Mir34a in a genetic mouse model of CAC.  
 
 
 
Figure 29. Altered expression of the IL6R/STAT3/miR-34a feedback loop components 
during EMT progression. During CRC progression, expression of miR-34a is down-
regulated by CpG methylation and p53 is inactivated by mutation. 
 
Results from this part of my study pointed out, that the activation of IL6R/Stat3 
signaling leads to EMT and invasion of colitis-associated tumors upon Mir34a-loss. 
However, the role of EMT in invasion and metastasis was challenged by recent 
publications: Zheng et al. demonstrated that deletion of the SNAIL1 and TWIST1 
genes in a pancreatic cancer mouse model does not attenuate metastasis (Zheng et 
al., 2015) and Fischer et al. showed by employing multiple transgenic mouse models 
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and establishing a cell lineage tracing approach together with characterization of 
epithelial and mesenchymal markers that EMT is not required in lung metastasis 
(Fischer et al., 2015). On the contrary, when ZEB1 was deleted in an identical 
pancreatic cancer model as used in Zheng et al., 40% reduction in metastasis was 
observed without an evidence for compensation by other EMT-transcription factors 
(Krebs et al., 2017). Therefore, these studies show that, there is a context-
dependency in the role and function of different EMT-transcription factors.  
Since the first part of this study focused on Mir34-deficiency in germ-line knock-
out mice, it is still unclear whether these observed effects were cell autonomous or if 
there was a contribution from the tumor stroma. To clarify that point, it would be 
useful to determine whether there are differences in abundance or function of stromal 
cell types in Mir34a-/- colon tumors compared to their Mir34aF/F controls. Tissue-
specific knock-out mouse models could be useful to clarify the role of Mir34a in 
stromal cells in CAC in the future.   
In the second part of this study, a cooperative role of Mir34a and Tp53 in the 
suppression of tumor initiation, invasion and metastasis was shown in a mouse 
model of sporadic CRC. These findings explain why colonic tumors with combined 
inactivation of both genes display the worst prognosis and poorest survival when 
compared to those with singular deletions of these genes. Interestingly, MIR34A is 
silenced by CpG methylation in late stage colorectal tumors (Wang et al., 2016). 
Since this is similar to the timing of mutational inactivation of TP53, the simultaneity 
of these events would allow their cooperation in CRC progression.  
Notably, Mir34aΔIECTp53ΔIEC mice displayed more tumor growth compared to 
single knockouts of Mir34aΔIEC and Tp53ΔIEC. In addition, Mir34aΔIECTp53ΔIEC mice 
demonstrated enhanced proliferation in the presence of DNA damage in 
Mir34a/Tp53-deficient IECs compared to other genotypes. Since, recent publications 
highlighted the role of miR-34a also in stemness (Bu et al., 2016; Park et al., 2014), it 
might be useful to further investigate whether combined inactivation of Mir34a and 
Tp53 also influences the stemness. 
Although Mir34a represents a direct Tp53 target, its loss further enhanced the 
effect of Tp53 deficiency in early and late stages of CRC formation and progression. 
This indicates that Mir34a may mediate tumor suppression downstream of other 
factors and pathways besides Tp53 and its upstream activating pathways. 
Interestingly, a previous study showed that activation of BRAF may cause a Tp53-
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independent induction of Mir34a expression via up-regulation of the transcription 
factor ELK1, which directly induces Mir34a (Bahrami et al., 2018; Christoffersen et 
al., 2010).   
Expression profiling revealed the activation of key oncogenic factors and 
pathways, such as c-Myc, EMT, hypoxia, and an inflammatory response in CRCs of 
Mir34aΔIECTp53ΔIEC mice. Recently Li et al., could show that the TP53 and MIR34a 
status are important determinants of the response to hypoxia (Li et al., 2017): only in 
colon cancer cells with inactivated TP53, MIR34a was directly repressed by hypoxia-
mediated activation of HIF-1α. The down-regulation of miR-34a was necessary for 
hypoxia-induced STAT3 activation and EMT, which may ultimately promote invasion 
and metastasis. Interestingly, the profiles of the tumors studied here also revealed a 
hypoxia-related signature in Mir34a/Tp53-deficient mice. In addition, we had 
previously described that miR-34a is directly repressed by STAT3 after IL6 exposure 
(Rokavec et al., 2014b). Indeed, the common epigenetic silencing of MIR34a 
observed in human CRCs may occur after prolonged HIF-1α- or STAT3-mediated 
repression of MIR34a.    
As miR-34a and Tp53 are commonly inactivated in human colorectal tumors, the 
genetic evidence for the cooperation between simultaneous loss of miR-34a and 
Tp53 provided here may have broad clinical implications. Since the restauration of wt 
TP53 or reactivation of mutant TP53 is hard to accomplish, tumors with inactivation 
of both TP53 and MIR34a may benefit from the treatment with MiR34a mimetics. 
Notably, MRX34, a liposome-formulated mimic of miR-34a, developed by Mirna 
Therapeutics, has been shown to have ability to reduce proliferation of various types 
of cancer cells, cause significant tumor regression in multiple mouse models, and to 
reduce the tumor forming capacity of cancer stem cells (Bader, 2012; Beg et al., 
2017). However, a multi-center, open label Phase 1 clinical trial to evaluate MRX34 
as a single agent in multiple advanced solid tumors and various hematological 
malignancies was stopped due to immune-related serious adverse events in some 
patients (Clinical trial information: NCT01829971). Therefore, more research has to 
be performed to clarify the contributions of carriers and miRNA mimics to the 
inflammatory responses (Reid et al., 2016). Additionally, miR-34a has recently been 
shown to target PDL1 and thereby antagonize the immune escape of cancer cells 
(Cortez et al., 2016; Wang et al., 2015). Therefore, this therapeutic approach may 
also harness the patient’s adaptive immune system against aggressive CRC. 
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Alternatively, as shown in this study, Mir34a-/Tp53-deficient CRCs may be treated 
with inhibitors directed towards miR-34a targets, which are up-regulated in these 
cancers. The up-regulation of these targets suggests that they are relevant for the 
etiology of the tumor. In addition, their up-regulation may result in a selective 
sensitivity of Mir34a-/Tp53-deficient colorectal tumors towards the respective 
inhibitors of these targets.   
Inhibition of the Mir34a targets IL6R and PAI-1 by using antibodies or small 
drug inhibitors may represent promising approaches to treat CRCs that display 
combined Tp53 and miR-34a loss: Here, we first focused on targeting IL6R since it 
represents a bona fide Mir34a target that activates the oncogenic transcription factor 
Stat3 (Rokavec et al., 2014b). Interestingly, treatment with an IL6R-neutralizing 
antibody was also shown to be effective in preventing metastasis in a lung 
colonization model (Lin et al., 2017). Furthermore, the IL6R-neutralizing antibody 
Tocillizumab was approved by the FDA for the treatment of chronic inflammatory 
diseases, such as rheumatoid and systemic juvenile idiopathic arthritis, Castleman 
disease, cytokine release syndrome and giant cell arteritis (Garbers et al., 2018; 
Johnson et al., 2018; Tanaka et al., 2012; Waldner et al., 2012). Therefore, IL6R 
targeting antibodies are well tolerated by the majority of patients and may therefore 
be employed to treat late stage CRC patients.  
In colonic tumors of Mir34aΔIECTp53ΔIEC mice, Pai-1 was one of the most 
significantly up-regulated genes. PAI-1 is a serine protease inhibitor (serpin) and the 
main regulator of the plasminogen activation system (Placencio and DeClerck, 2015). 
It inhibits tissue-type plasminogen activator (tPA) and urokinase-type plasminogen 
activator (uPA). Roles of PAI-1 in tumorigenesis are: (1) Leading to angiogenesis or 
intracellular apoptotic signaling by inhibition of uPA action to prevent the cleavage of 
plasminogen into plasmin and subsequent substrates on the cell surface; (2) it leads 
to intracellular signaling and cell migration by its ability to bind lipoprotein receptor-
related protein (LRP1); and (3) promotes endothelial cell migration and angiogenesis 
by binding to vitronectin in the extracellular matrix (Placencio and DeClerck, 2015). 
PAI-1 can be produced by tumor cells and non-malignant cells, including endothelial 
cells (EC), macrophages or adipocytes in the tumor microenvironment and it can 
have paracrine or autocrine effects within the tumor microenvironment (Giacoia et al., 
2014; Placencio and DeClerck, 2015). In this study, the most pronounced PAI1 
expression was detected in tumor cells in the center and at the invasion front of 
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colorectal tumors with simultaneous inactivation of MIR34A and TP53. At the 
invasion front of these tumors PAI-1 may promote the budding of cancer cells by 
enhancing invasion-related processes, such as remodeling of the extracellular matrix. 
Notably, detection of PAI-1 is used as a prognostic marker for node-negative breast 
cancer since 2007 (Harbeck et al., 2013; Harris et al., 2007). Therefore, up-regulation 
of PAI-1 might represent not only a new therapeutic target but also an attractive 
prognostic marker for MIR34A/TP53-deficient colorectal tumors. 
 
 
 
 
Figure 30. Graphical summary of combined inactivation of Tp53 and Mir34a in CRC. 
Tp53 and Mir34a cooperatively promote colorectal cancer development and progression via 
increasing levels of IL6R and PAI-1. 
 
Tumor volume of human T24 bladder and HeLa cervical cancer 
xenotransplants in mice was reduced after oral administration of Tiplaxtinin (Gomes-
Giacoia et al., 2013). In addition, the Pai1-inhibitors SK-116 and SK-216 were able to 
decrease the number of small intestinal polyps in Apc/Apc1638N mice (Mutoh et al., 
2008). Although, others and we showed that targeting Pai-1 in cancer is an attractive 
therapeutic approach, limitations, such as the short half-live of these inhibitors, 
indicate that alternative Pai-1 inhibitors with improved pharmacologic profiles should 
be developed. 
As previously shown, carcinogen challenge inducing activating mutations in 
the Ctnnb gene in Tp53ΔIEC mice promotes invasive and metastatic colorectal tumors 
(Schwitalla et al., 2013). Tumorigenesis in the Tp53ΔIEC mice model was also 
accompanied by formation of NF-κB dependent inflammatory microenvironment, 
which could also be detected in human colorectal cancer (Schwitalla et al., 2013). 
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Therefore, we chose the well-established Tp53ΔIEC mice model to generate 
Mir34aΔIECTp53ΔIEC mice. As it was described in the second part of this study, tumor 
initiation and progression in Mir34aΔIECTp53ΔIEC mice were further enhanced 
compared to Tp53ΔIEC mice and metastasis formation was accelerated by 8 weeks. 
Therefore, this model may be useful for testing metastasis targeting strategies. In 
fact, experiments employing the IL6Ra neutralizing antibody and Tiplaxtinin were 
only applied to Mir34aΔIECTp53ΔIEC mice, since only those developed lymph node 
metastasis in 16 weeks.   
  The consequence of deleting exons 2 to 10, that was employed here to 
inactivate Tp53, corresponds to the effects of loss-of-function mutations of Tp53 that 
occur in ~50% of all CRCs (Bouaoun et al., 2016). Whether gain-of-function Tp53 
mutations, which occur at a lower frequency, have divergent effects in combination 
with the inactivation of miR-34a remains to be determined in the future.    
In conclusion, this study provides genetic evidence for a role of the combined 
inactivation of Mir34a and Tp53 in the initiation and progression of CRC. In addition, 
the up-regulated Mir34a-targets identified in Mir34a- and p53-deficient colonic tumors 
in this study provide a valuable resource for the future identification and 
characterization of therapeutic targets, as shown by the example of IL6R and Pai-1. 
Taken together, this study demonstrated the role of Mir34a as a tumor 
suppressor in in vivo models of colorectal cancer and highlighted the importance of 
Mir34a targets for colorectal cancer treatment. 
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6 Summary 
In this study, the potential role of miR-34a as a tumor suppressor in mouse 
models of carcinogen-induced colorectal cancer and colitis-associated cancer was 
investigated. 
In the first part, I demonstrated that germline deletion of Mir34a promotes 
inflammation-induced colorectal carcinogenesis in mice. In a colitis-associated 
cancer model Mir34a-deficiency was associated with an increase in the frequency 
and size of colon tumors, and enhanced invasion into surrounding tissue. Mir34a-
deficient colon tumors displayed IL6R/Stat3 pathway activation with elevated 
expression of EMT markers, such as Snail and Zeb1, which might explain the 
observed invasive characteristics of these colon tumors. Therefore, this study 
provided first in vivo proof for a tumor suppressive function of Mir34a in a genetic 
mouse model of CAC. 
It was previously shown that miR-34a is a down-stream target of tumor 
suppressor Tp53. Inactivation of both TP53 (by mutation) and MIR34A (by CpG 
methylation) occurs in late stages of colorectal carcinogenesis. In the second part of 
this study we found that TP53 and the MIR34A were inactivated in 50% of CRCs 
which developed distant metastases. To trace the consequences of this combined 
inactivation, I deleted these genes in a mouse model of colorectal cancer, and 
characterized the CRC initiation and progression. RNA expression profiling of colon 
tumors revealed the activation of key oncogenic factors and pathways, such as c-
Myc, EMT, hypoxia, and an inflammatory response in Mir34aΔIECTp53ΔIEC mice. 
Treatment of Mir34aΔIECTp53ΔIEC mice with inhibitors of up-regulated Mir34a targets, 
as exemplarily demonstrated here for IL6R and Pai-1, reduced tumor progression 
and inhibited the lymph-node metastasis. Analysis of 628 colon cancer cases 
represented in online databases and 61 primary tissue samples obtained from 
patients demonstrated that the findings made in a preclinical mouse model can be 
transferred to humans.  
Taken together, the results obtained within this study improved the 
understanding of the role of miR-34a in colorectal cancer and underlined the 
therapeutic potential of miR-34a targets as an alternative approach for the treatment 
of colorectal cancer. 
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7 Zusammenfassung 
In dieser Arbeit wurde die potentielle Wirkung von miR-34a als Tumorsuppressor 
in einem karzinogen-induzierten und einem Kolitis-assoziierten Mausmodell für das 
Kolorektale Karzinom untersucht.  
Im ersten Teil der Arbeit zeigte ich, dass die Deletion von Mir34a in der 
Keimbahn von Mäusen die Entstehung von Entzündungs-induzierten Darmkrebs 
verstärkt. Verlust von Mir34a führte im Modell für Kolitis-assoziierten Krebs zu 
erhöhter Zahl und Größe von Tumoren und förderte deren Invasion in benachbarte 
Strukturen. In Mir34a-defizienten Darmtumoren zeigte sich eine Aktivierung des 
IL6R/Stat3-Signalwegs mit verstärkter Expression von EMT Genen, wie z.B. Snail 
und Zeb1, was die beobachteten invasiven Eigenschaften dieser Darmtumoren 
erklären könnte. Diese Arbeit stellt den ersten in vivo Beweis für eine 
tumorsuppressive Wirkung von Mir34a in einem genetischen Modell für Kolitis-
assoziiertem Krebs dar. 
Es war bereits bekannt, dass miR-34a ein nachgeschaltetes Zielgen des 
Tumorsuppressors p53 (TP53) ist. Im fortgeschrittenen Stadium von Kolorektal-
karzinomen (KRK) kommt es zur Inaktivierung von TP53 (durch Mutation) und von 
MIR34A (durch CpG Methylierung). Im zweiten Teil der Studie beschreiben wir, dass 
in jedem zweiten KRK mit Fernmetastasen sowohl TP53, als auch MIR-34A 
inaktiviert waren. Um die Folgen dieser kombinierten Inaktivierung aufzuspüren habe 
ich diese Gene in einem Modell für sporadisches Kolorektales Karzinom simultan 
deletiert und die frühe und fortgeschrittene Phase der Tumorentwicklung untersucht. 
Untersuchungen des Expressionsprofils von RNA in Darmtumoren zeigte die 
Aktivierung von zentralen onkogenen Faktoren und Signalwegen wie c-Myc, EMT, 
Hypoxie und Tumor-assoziierte Entzündung in Mir34aΔIECTp53ΔIEC Mäusen. Die 
Behandlung dieser Mäuse mit Inhibitoren aktivierter Mir34a Zielgene, wie hier 
exemplarisch für IL6R und Pai-1 gezeigt, reduzierte die Tumorentwicklung und 
blockierte die Entstehung von Lymphknotenmetastasen. Die Analyse von 628 
Darmkrebsfällen aus Datenbanken und von 61 Gewebeproben von Patienten zeigte 
die Übertragbarkeit der Ergebnisse aus dem präklinischen Mausmodell auf den 
Menschen. 
Zusammengefasst vertiefen die Ergebnisse dieser Arbeit unser Verständnis der 
Folgen einer Mir34a-Inaktivierung in Krebszellen und unterstreichen das 
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therapeutisches Potential von miR-34a-Zielgenen als alternativen Ansatz in der 
Behandlung von Darmkrebs. 
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9.1 50 mRNAs most significantly, positively associated with increased tumor 
aggressiveness 
 
 
mRNAs were ranked according to t-test for trend (A) based on Spearman correlation (B) 
between mRNA expression as determined by RNA-Seq and genotypes ranked in the order: 
Mir34aFl/Fl/Tp53Fl/Fl, Mir34aΔIEC, Tp53ΔIEC, Mir34aΔIECTp53ΔIEC, since the degree of tumor 
aggressiveness (tumor number/size/invasiveness) increased in this order. Differential 
expression between tumors with the 4 different genotypes is indicated in columns 4-10.  Fold 
changes were calculated by dividing normalized RNAseq counts between indicated 
genotypes.  
mRNA
p-value 
(t-test for trend)  A
Correl.with tumor 
agressiveness B
Fold change
 Mir34a ΔIEC /
Mir34a Fl/Fl Tp53 Fl/Fl
Fold change
 Tp53 ΔIEC /
Mir34a Fl/Fl Tp53 Fl/Fl
Fold change
 Mir34a ΔIEC Tp53 ΔIEC /
Mir34a Fl/Fl Tp53 Fl/Fl
Fold change
 Tp53 ΔIEC /Mir34a ΔIEC
Fold change
 Mir34a ΔIEC  Tp53 ΔIEC /
Mir34a ΔIEC
Fold change
Mir34a ΔIEC Tp53 ΔIEC /
Tp53 ΔIEC
RP23-352D14.1 0.00002 0.92500 10.00 9.00 19.00 0.90 1.90 2.11
Ctla2a 0.00002 0.92176 1.77 1.99 4.07 1.13 2.30 2.04
Lrrc8d 0.00002 0.92176 1.16 1.08 1.29 0.93 1.12 1.20
Gm5466 0.00006 0.90327 2.37 2.47 5.23 1.04 2.21 2.12
Gpihbp1 0.00007 0.89801 2.19 2.25 5.56 1.03 2.54 2.47
Egf 0.00011 0.88940 1.60 1.56 1.68 0.98 1.05 1.08
2700062C07Rik 0.00012 0.88763 1.13 1.21 1.40 1.07 1.23 1.15
Cdh5 0.00012 0.88763 2.41 2.16 3.72 0.90 1.54 1.72
Flt1 0.00012 0.88763 1.86 1.54 3.71 0.83 1.99 2.40
Ftsj1 0.00012 0.88763 1.07 1.14 1.48 1.07 1.38 1.30
Scd1 0.00012 0.88763 1.98 1.41 2.74 0.71 1.39 1.95
Sox7 0.00012 0.88763 1.79 2.17 3.76 1.21 2.11 1.74
Ovgp1 0.00019 0.87623 1.12 1.51 2.04 1.35 1.82 1.35
Serpina10 0.00023 0.87074 0.00 0.00 0.00 0.40 2.80 7.00
Gng11 0.00034 0.85977 1.92 1.45 3.11 0.75 1.62 2.15
Gm5913 0.00041 0.85349 2.17 1.86 3.21 0.86 1.48 1.72
Abcf3 0.00041 0.85349 1.08 1.09 1.32 1.01 1.23 1.22
Atp5s 0.00041 0.85349 1.24 1.18 1.51 0.95 1.22 1.28
Eno1 0.00041 0.85349 1.90 1.20 2.15 0.63 1.13 1.79
Hist3h2ba 0.00041 0.85349 1.97 1.81 2.91 0.92 1.48 1.61
Pus7l 0.00041 0.85349 1.33 1.39 1.83 1.05 1.37 1.31
Rars 0.00041 0.85349 1.10 1.27 1.46 1.15 1.32 1.15
Trak2 0.00041 0.85349 1.14 1.14 1.30 1.00 1.14 1.13
AU021092 0.00056 0.84395 1.89 1.18 2.54 0.62 1.34 2.15
Ctla2b 0.00056 0.84395 2.22 2.56 4.00 1.15 1.80 1.57
RP23-415E17.1 0.00068 0.83735 1.36 2.46 3.20 1.81 2.36 1.30
Evc 0.00070 0.83643 1.20 0.93 2.47 0.78 2.06 2.64
Gm14295 0.00070 0.83636 2.68 1.43 20.64 0.53 7.71 14.45
Gm4609 0.00083 0.83028 0.00 0.00 0.00 1.00 2.00 2.00
Slc10a6 0.00086 0.82874 3.00 3.00 8.00 1.00 2.67 2.67
Cfhr3 0.00089 0.82783 1.45 1.36 2.27 0.94 1.56 1.67
Pcdhb7 0.00093 0.82602 2.15 1.77 3.31 0.82 1.54 1.87
Gm13722 0.00098 0.82407 1.33 1.83 40.00 1.38 30.00 21.82
Peg10 0.00099 0.82353 2.40 2.80 4.40 1.17 1.83 1.57
Lingo1 0.00106 0.82103 1.86 3.00 3.71 1.62 2.00 1.24
Pai-1 0.00111 0.81935 1.97 3.34 4.29 1.69 2.17 1.29
9430016H08Rik 0.00111 0.81935 1.09 1.27 1.41 1.17 1.29 1.10
Apobec3 0.00111 0.81935 1.53 1.08 3.81 0.71 2.50 3.53
Fabp4 0.00111 0.81935 1.88 1.40 3.57 0.75 1.90 2.55
Fam132b 0.00111 0.81935 1.17 1.21 1.65 1.04 1.41 1.36
Gm5883 0.00111 0.81935 2.14 2.24 3.10 1.05 1.45 1.38
Hspa4 0.00111 0.81935 0.99 1.06 1.20 1.07 1.21 1.13
Iba57 0.00111 0.81935 1.18 1.24 1.47 1.05 1.24 1.19
Kcnj8 0.00111 0.81935 1.39 2.15 3.02 1.55 2.18 1.41
Msto1 0.00111 0.81935 1.17 1.30 1.77 1.11 1.51 1.36
Plcg2 0.00111 0.81935 1.26 1.07 1.78 0.85 1.41 1.66
Sparcl1 0.00111 0.81935 1.77 1.41 2.44 0.80 1.38 1.74
Tanc2 0.00111 0.81935 1.71 1.20 2.48 0.70 1.45 2.07
Tmem97 0.00111 0.81935 1.50 1.53 1.96 1.02 1.31 1.28
Zscan25 0.00111 0.81935 1.10 1.28 1.52 1.16 1.38 1.19
 Supplementary Tables 9 
89 
9.2 50 mRNAs most significantly, negatively associated with increased tumor 
aggressiveness  
 
 
mRNAs were ranked according a t-test for trend (A) based on Spearman correlation (B) 
between mRNA expression as determined by RNA-Seq and genotypes ranked in the order: 
Mir34aFl/Fl/Tp53Fl/Fl, Mir34aΔIEC, Tp53ΔIEC, Mir34aΔIECTp53ΔIEC, since the degree of tumor 
aggressiveness (tumor number/size/invasiveness) increased in this order. Differential 
expression between tumors with the 4 different genotypes is indicated in columns 4-10.  Fold 
changes were calculated by dividing normalized RNAseq counts between indicated 
genotypes.  
mRNA
p-value 
(t-test for trend) A 
Correl.with tumor 
agressiveness B
Fold change
Mir34a ΔIEC /
Mir34a Fl/Fl Tp53 Fl/Fl
Fold change
Tp53 ΔIEC /
Mir34a Fl/Fl Tp53 Fl/Fl
Fold change
Mir34a ΔIEC Tp53 ΔIEC /
Mir34a Fl/Fl Tp53 Fl/Fl
Fold change
Tp53 ΔIEC /Mir34a ΔIEC
Fold change
Mir34a ΔIEC  Tp53 ΔIEC /
Mir34a ΔIEC
Fold change
Mir34a ΔIEC Tp53 ΔIEC /
T p53 ΔIEC
Cyp2d11 0.00002 -0.92300 0.59 0.54 0.14 0.92 0.24 0.26
Acvr1b 0.00002 -0.92176 0.90 0.83 0.58 0.93 0.65 0.70
Aqp8 0.00002 -0.92176 0.51 0.34 0.01 0.67 0.03 0.04
Kcnmb2 0.00008 -0.89629 0.79 0.83 0.59 1.05 0.75 0.72
Mgat4c 0.00009 -0.89416 0.77 0.65 0.26 0.84 0.34 0.41
Clca6 0.00012 -0.88763 0.60 0.26 0.09 0.44 0.14 0.33
Dnal4 0.00012 -0.88763 0.79 0.75 0.60 0.95 0.76 0.80
Ggh 0.00012 -0.88763 0.69 0.53 0.18 0.77 0.26 0.34
H2-Q1 0.00012 -0.88763 0.59 0.53 0.25 0.89 0.43 0.48
Khnyn 0.00012 -0.88763 0.97 0.92 0.58 0.94 0.59 0.63
Lzic 0.00012 -0.88763 0.85 0.73 0.54 0.85 0.63 0.74
Mcl1 0.00012 -0.88763 0.89 0.83 0.62 0.94 0.69 0.74
Siva1 0.00012 -0.88763 0.80 0.85 0.57 1.06 0.72 0.68
Stk35 0.00012 -0.88763 0.95 0.93 0.81 0.99 0.85 0.86
Tmigd1 0.00016 -0.87950 0.45 0.31 0.14 0.68 0.30 0.44
Ube2a 0.00019 -0.87571 0.93 0.78 0.75 0.83 0.81 0.97
Pnldc1 0.00023 -0.86992 0.61 0.53 0.47 0.87 0.77 0.89
Rnf39 0.00027 -0.86594 0.67 0.73 0.31 1.10 0.46 0.42
Srsf4 0.00029 -0.86403 0.90 0.93 0.77 1.03 0.86 0.83
Nlrp9b 0.00029 -0.86403 0.70 0.42 0.31 0.60 0.44 0.74
Lrrc69 0.00041 -0.85373 0.93 0.79 0.68 0.86 0.73 0.85
Agrn 0.00041 -0.85349 0.82 0.77 0.58 0.94 0.71 0.75
BC022687 0.00041 -0.85349 0.83 0.88 0.56 1.06 0.68 0.64
Ces2c 0.00041 -0.85349 0.63 0.56 0.28 0.88 0.44 0.51
Dnase1l1 0.00041 -0.85349 0.85 0.77 0.72 0.91 0.85 0.94
Gnb1 0.00041 -0.85349 0.93 0.90 0.80 0.97 0.86 0.89
Grm8 0.00041 -0.85349 0.73 0.64 0.16 0.88 0.22 0.25
Mboat1 0.00041 -0.85349 0.76 0.88 0.34 1.15 0.45 0.39
Mfsd7a 0.00041 -0.85349 0.70 0.51 0.20 0.73 0.28 0.39
Mtfr1l 0.00041 -0.85349 0.83 0.86 0.63 1.04 0.77 0.74
Nmnat1 0.00041 -0.85349 0.70 0.67 0.52 0.95 0.75 0.79
Rab3b 0.00041 -0.85349 0.51 0.33 0.15 0.65 0.28 0.44
Rassf3 0.00041 -0.85349 0.87 0.79 0.63 0.91 0.72 0.80
Rsrp1 0.00041 -0.85349 0.86 0.47 0.39 0.54 0.46 0.84
Smim19 0.00041 -0.85349 0.82 0.86 0.76 1.04 0.92 0.88
Tmem139 0.00041 -0.85349 0.72 0.50 0.29 0.70 0.40 0.58
Ttc22 0.00041 -0.85349 0.85 0.69 0.38 0.81 0.45 0.55
Upk1a 0.00041 -0.85349 0.66 0.32 0.21 0.48 0.32 0.66
Zdhhc1 0.00041 -0.85349 0.81 0.73 0.65 0.90 0.80 0.90
Slc5a12 0.00044 -0.85127 0.87 0.50 0.33 0.58 0.38 0.67
Gm12648 0.00046 -0.84986 0.92 0.67 0.57 0.72 0.61 0.85
D330041H03Rik 0.00049 -0.84782 0.68 0.65 0.54 0.95 0.78 0.83
Cyp2d34 0.00056 -0.84353 0.71 0.65 0.16 0.91 0.23 0.25
Tmem240 0.00068 -0.83735 0.93 0.69 0.34 0.74 0.37 0.50
1700031M16Rik 0.00069 -0.83675 0.54 0.49 0.38 0.90 0.70 0.78
Rbp2 0.00070 -0.83636 0.85 0.39 0.17 0.46 0.20 0.43
RP24-492O4.4 0.00070 -0.83636 0.71 0.77 0.47 1.08 0.67 0.62
Krt27 0.00082 -0.83080 0.29 1.41 0.11 4.83 0.37 0.08
5730422E09Rik 0.00095 -0.82538 0.79 0.76 0.62 0.96 0.78 0.81
Olfr165 0.00095 -0.82535 0.33 0.14 0.02 0.42 0.05 0.13
Cyp2b13 0.00095 -0.82535 0.55 0.48 0.26 0.86 0.47 0.54
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9.3 List of up-regulated mRNAs in Mir34aΔIEC and/or Tp53ΔIEC- deficient 
colonic tumors enriched in the Hallmark Myc targets V2 gene set 
 
 
mRNAs were ranked according a t-test for trend (A) based on Spearman correlation (B) 
between mRNA expression as determined by RNA-Seq and genotypes ranked in the order: 
Mir34aFl/Fl/Tp53Fl/Fl, Mir34aΔIEC, Tp53ΔIEC, Mir34aΔIECTp53ΔIEC, since the degree of tumor 
aggressiveness (tumor number/size/invasiveness) increased in this order.  
mRNA Description p-value A Correlation B
TMEM97 transmembrane protein 97 0.00111 0.81935
FARSA phenylalanyl-tRNA synthetase, alpha subunit 0.00869 0.71693
WDR74 WD repeat domain 74 0.00869 0.71693
LAS1L LAS1-like (S. cerevisiae) 0.00869 0.71693
AIMP2 aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 0.01440 0.68279
DDX18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 0.01440 0.68279
SLC19A1 solute carrier family 19 (folate transporter), member 1 0.01440 0.68279
IMP4 IMP4, U3 small nucleolar ribonucleoprotein, homolog (yeast) 0.01440 0.68279
RRP9 ribosomal RNA processing 9, small subunit (SSU) processome component, homolog (yeast) 0.02250 0.64865
PA2G4 proliferation-associated 2G4, 38kDa 0.02250 0.64865
MYBBP1A MYB binding protein (P160) 1a 0.02250 0.64865
RCL1 RNA terminal phosphate cyclase-like 1 0.02250 0.64865
SRM spermidine synthase 0.03349 0.61451
NOC4L nucleolar complex associated 4 homolog (S. cerevisiae) 0.03349 0.61451
RRP12 ribosomal RNA processing 12 homolog (S. cerevisiae) 0.04788 0.58037
NOP2 NOP2 nucleolar protein homolog (yeast) 0.04788 0.58037
SUPV3L1 suppressor of var1, 3-like 1 (S. cerevisiae) 0.04788 0.58037
NIP7 nuclear import 7 homolog (S. cerevisiae) 0.04788 0.58037
IPO4 importin 4 0.04788 0.58037
GRWD1 glutamate-rich WD repeat containing 1 0.04788 0.58037
Hallmark Myc Targets V2
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9.4 List of up-regulated mRNAs in Mir34aΔIEC and/or Tp53ΔIEC- deficient 
colonic tumors enriched in the Hallmark Myc targets V1 gene set 
 
 
 
mRNAs were ranked according a t-test for trend (A) based on Spearman correlation (B) 
between mRNA expression as determined by RNA-Seq and genotypes ranked in the order: 
Mir34aFl/Fl/Tp53Fl/Fl, Mir34aΔIEC, Tp53ΔIEC, Mir34aΔIECTp53ΔIEC, since the degree of tumor 
aggressiveness (tumor number/size/invasiveness) increased in this order.  
mRNA Description p-value A Correlation B
HDDC2 HD domain containing 2 0.00487 0.75107
ABCE1 ATP-binding cassette, sub-family E (OABP), member 1 0.00869 0.71693
SF3A1 splicing factor 3a, subunit 1, 120kDa 0.00869 0.71693
PRPF31 PRP31 pre-mRNA processing factor 31 homolog (S. cerevisiae) 0.00869 0.71693
CCT3 chaperonin containing TCP1, subunit 3 (gamma) 0.00869 0.71693
AIMP2 aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 0.01440 0.68279
DDX18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 0.01440 0.68279
PWP1 PWP1 homolog (S. cerevisiae) 0.01440 0.68279
EIF3B eukaryotic translation initiation factor 3, subunit B 0.01440 0.68279
NME1 non-metastatic cells 1, protein (NM23A) expressed in 0.01764 0.66780
RRP9 ribosomal RNA processing 9, small subunit (SSU) processome component, homolog (yeast) 0.02250 0.64865
PA2G4 proliferation-associated 2G4, 38kDa 0.02250 0.64865
SRM spermidine synthase 0.03349 0.61451
G3BP1 GTPase activating protein (SH3 domain) binding protein 1 0.03349 0.61451
EIF1AX eukaryotic translation initiation factor 1A, X-linked 0.03349 0.61451
CCT5 chaperonin containing TCP1, subunit 5 (epsilon) 0.03349 0.61451
ILF2 interleukin enhancer binding factor 2, 45kDa 0.03349 0.61451
TCP1 t-complex 1 0.03349 0.61451
TUFM Tu translation elongation factor, mitochondrial 0.03349 0.61451
EIF3D eukaryotic translation initiation factor 3, subunit D 0.04788 0.58037
KARS lysyl-tRNA synthetase 0.04788 0.58037
EIF4A1 eukaryotic translation initiation factor 4A1 0.04788 0.58037
GSPT1 G1 to S phase transition 1 0.04788 0.58037
POLD2 polymerase (DNA directed), delta 2, regulatory subunit 50kDa 0.04788 0.58037
PSMB2 proteasome (prosome, macropain) subunit, beta type, 2 0.04788 0.58037
FBL fibrillarin 0.04788 0.58037
UBE2L3 ubiquitin-conjugating enzyme E2L 3 0.04788 0.58037
CAD carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase 0.04788 0.58037
Hallmark Myc Targets V1
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9.5 List of up-regulated mRNAs in Mir34aΔIEC and/or Tp53ΔIEC- deficient 
colonic tumors enriched in the Hallmark Hypoxia gene set 
 
 
 
mRNAs were ranked according a t-test for trend (A) based on Spearman correlation (B) 
between mRNA expression as determined by RNA-Seq and genotypes ranked in the order: 
Mir34aFl/Fl/Tp53Fl/Fl, Mir34aΔIEC, Tp53ΔIEC, Mir34aΔIECTp53ΔIEC, since the degree of tumor 
aggressiveness (tumor number/size/invasiveness) increased in this order.  
mRNA Description p-value A Correlation B
ENO1 enolase 1, (alpha) 0.00041 0.85349
PAI-1 plasminogen activator inhibitor 1 0.00111 0.81935
GAA glucosidase, alpha; acid 0.00247 0.78544
CAV1 caveolin 1, caveolae protein, 22kDa 0.00248 0.78521
PYGM phosphorylase, glycogen, muscle 0.00866 0.71714
TGM2 transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) 0.00869 0.71693
CTGF connective tissue growth factor 0.00869 0.71693
LOX lysyl oxidase 0.00869 0.71693
CP ceruloplasmin (ferroxidase) 0.00869 0.71693
IGFBP3 insulin-like growth factor binding protein 3 0.01440 0.68279
TPI1 triosephosphate isomerase 1 0.01440 0.68279
IL6 interleukin 6 (interferon, beta 2) 0.01440 0.68279
ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 0.01440 0.68279
GRHPR glyoxylate reductase/hydroxypyruvate reductase 0.01440 0.68279
ALDOC aldolase C, fructose-bisphosphate 0.01440 0.68279
CHST3 carbohydrate (chondroitin 6) sulfotransferase 3 0.02250 0.64865
GAPDH glyceraldehyde-3-phosphate dehydrogenase 0.03349 0.61451
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 0.03349 0.61451
ATP7A ATPase, Cu++ transporting, alpha polypeptide 0.03349 0.61451
ANGPTL4 angiopoietin-like 4 0.04208 0.59312
PGM1 phosphoglucomutase 1 0.04788 0.58037
SCARB1 scavenger receptor class B, member 1 0.04788 0.58037
Hallmark Hypoxia
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9.6 List of up-regulated mRNAs in Mir34aΔIEC and/or Tp53ΔIEC- deficient 
colonic tumors enriched in the Hallmark Epithelial Mesenchymal 
Transition gene set 
 
 
mRNAs were ranked according a t-test for trend (A) based on Spearman correlation (B) 
between mRNA expression as determined by RNA-Seq and genotypes ranked in the order: 
Mir34aFl/Fl/Tp53Fl/Fl, Mir34aΔIEC, Tp53ΔIEC, Mir34aΔIECTp53ΔIEC, since the degree of tumor 
aggressiveness (tumor number/size/invasiveness) increased in this order.  
mRNA Description p-value A Correlation B
PAI-1 plasminogen activator inhibitor 1 0.00111 0.81935
TFPI2 tissue factor pathway inhibitor 2 0.00248 0.78521
MEST mesoderm specific transcript homolog (mouse) 0.00487 0.75107
PRRX1 paired related homeobox 1 0.00866 0.71714
TGM2 transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) 0.00869 0.71693
CTGF connective tissue growth factor 0.00869 0.71693
LOX lysyl oxidase 0.00869 0.71693
IGFBP3 insulin-like growth factor binding protein 3 0.01440 0.68279
CD44 CD44 molecule (Indian blood group) 0.01440 0.68279
IL6 interleukin 6 (interferon, beta 2) 0.01440 0.68279
NOTCH2 notch 2 0.01440 0.68279
PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 0.01527 0.67857
MMP14 matrix metallopeptidase 14 (membrane-inserted) 0.02250 0.64865
COL4A1 collagen, type IV, alpha 1 0.02250 0.64865
TNFRSF11B tumor necrosis factor receptor superfamily, member 11b 0.02250 0.64865
RGS4 regulator of G-protein signaling 4 0.02250 0.64865
FBN2 fibrillin 2 0.02250 0.64865
MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) 0.03827 0.60218
CXCL12 chemokine (C-X-C motif) ligand 12 0.04788 0.58037
COL4A2 collagen, type IV, alpha 2 0.04788 0.58037
COL5A3 collagen, type V, alpha 3 0.04788 0.58037
Hallmark Epithelial Mesenchymal Transition
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9.7 List of up-regulated mRNAs in Mir34aΔIEC and/or Tp53ΔIEC- deficient 
colonic tumors enriched in the Hallmark Inflammatory Response gene set 
 
 
 
mRNAs were ranked according a t-test for trend (A) based on Spearman correlation (B) 
between mRNA expression as determined by RNA-Seq and genotypes ranked in the order: 
Mir34aFl/Fl/Tp53Fl/Fl, Mir34aΔIEC, Tp53ΔIEC, Mir34aΔIECTp53ΔIEC, since the degree of tumor 
aggressiveness (tumor number/size/invasiveness) increased in this order. 
  
mRNA Description p-value A Correlation B
PAI-1 plasminogen activator inhibitor 1 0.00111 0.81935
TNFRSF9 tumor necrosis factor receptor superfamily, member 9 0.00433 0.75746
SLC28A2 solute carrier family 28 (sodium-coupled nucleoside transporter), member 2 0.00672 0.73272
CCL5 chemokine (C-C motif) ligand 5 0.00690 0.73110
IL6 interleukin 6 (interferon, beta 2) 0.01440 0.68279
PROK2 prokineticin 2 0.02123 0.65332
MMP14 matrix metallopeptidase 14 (membrane-inserted) 0.02250 0.64865
SLC11A2 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 0.02250 0.64865
CSF3 colony stimulating factor 3 (granulocyte) 0.02616 0.63617
SELL selectin L 0.02616 0.63617
CXCL9 chemokine (C-X-C motif) ligand 9 0.03030 0.62348
FPR1 formyl peptide receptor 1 0.03827 0.60218
GP1BA glycoprotein Ib (platelet), alpha polypeptide 0.04780 0.58054
IL18RAP interleukin 18 receptor accessory protein 0.04788 0.58037
CCL20 chemokine (C-C motif) ligand 20 0.04788 0.58037
CD14 CD14 molecule 0.04788 0.58037
MARCO macrophage receptor with collagenous structure 0.04788 0.58037
SLC7A2 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 0.04949 0.57702
Hallmark Inflammatory Response
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